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 In 1863, Rudolf Virchow proposed that tumors arise from sites of chronic inflammation. 
This concept was largely ignored throughout the majority of the next century as the genetic basis 
of cancer was explored. However, it has become well appreciated that inflammation and cancer 
are intimately linked. For example, chronic inflammation of the intestine in the form of 
Inflammatory Bowel Disease (IBD) predisposes to the development of colon cancer. Although 
the vast majority of colon tumors do not arise from sites of chronic inflammation, sporadic colon 
tumors elicit an inflammatory response that is essential for tumor growth, progression, and 
evasion of anti-tumor immunity.  
 Hypoxia is a well-characterized feature of nearly all solid tumors and promotes 
stabilization of the hypoxia inducible transcription factors (HIF-1α and HIF-2α) with known 
roles in modulating tumor-associated inflammation. We have previously reported that intestinal 
epithelial HIF-2α is an important driver of the acute inflammatory response in colitis. The 
present work describes a novel axis by which intestinal epithelial HIF-2α serves as a critical link 
between inflammation and cancer of the colon. Mechanistically, our work shows a crucial role 
for intestinal epithelial HIF-2α in regulation of the immune microenvironment of colon tumors 
through recruitment of intra-tumoral neutrophils. Neutrophils are granulocytic myeloid cells of 
the innate immune system that are the first responders to sites of infection to limit microbes. 
 ix 
Neutrophils are highly infiltrated in nearly all solid tumors including colon cancer. We showed 
that neutrophil influx was due to direct HIF-2α-dependent regulation of the potent neutrophil 
chemokine CXCL1. These data identify a novel role for HIF-2α in modulation of the tumor 
immune microenvironment of inflammation-driven colon tumors and suggest therapeutic 
potential.  
 Our data suggested an important role for neutrophils in the maintenance of colon tumors. 
However, the importance of neutrophils in the initiation of colon tumorigenesis is largely 
unknown. Using mice with constitutive genetic depletion of neutrophils, the present work 
demonstrates an essential role for neutrophils in restricting colon tumor growth and progression 
in both inflammation-driven and sporadic colon tumor models. Neutrophil depletion correlated 
with robust expansion of colon-tumor associated microbiota and tumor-associated B-cells, both 
of which had important roles in neutrophil-deficient colon tumorigenesis. Together, our data 
suggest divergent roles for neutrophils in the initiation and maintenance of colon tumors.  
 The work presented in this thesis also shows an important role for the transcription factor, 
myc-associated zinc finger (MAZ) in colitis and colon cancer. MAZ is an inflammation induced 
transcription factor that has a previously identified role as a HIF-2α transcriptional cofactor. We 
show that MAZ is highly active in human colitis and colon cancer. The present work delineates a 
critical function for MAZ in the inflammatory progression of colitis and colon cancer through 
regulation of oncogenic STAT3 signaling. Collectively, these studies shed new light onto the 








The tumor microenvironment is similar to an inflammatory focus as it consists of a 
complex milieu of both innate and adaptive immune cells (1). Hypoxia is a characteristic feature 
of both tumors and inflammatory foci. Increased metabolic demand from rapid cell turnover, 
immune cell infiltration, and vascular disruption cause local O2 tension to decline. The decreased 
O2 tension of tumors or inflamed tissue promotes activation of HIFs. HIFs are basic helix-loop-
helix-per-arnt-sim (bHLH-PAS) containing transcription factors consisting of a heterodimer of 
an oxygen-sensitive a subunit (HIF-1a, HIF-2a, and HIF-3a) and a constitutively expressed β 
subunit (ARNT) (2). HIF-1a is ubiquitously expressed whereas HIF-2a and HIF-3a expression 
is more tissue restricted (3-5). HIF-a subunits are regulated by O2-dependent post-translational 
hydroxylation of two specific proline residues by prolyl hydroxylase domain-containing (PHD-
containing) enzymes. In normoxia, HIF hydroxylation leads to association with the von-Hippel 
Lindau (VHL) tumor suppressor/E3 ubiquitin ligase complex, ubiquitin conjugation, and 26s 
proteasomal degradation. As O2 homeostasis is disrupted and O2 concentration declines under 
inflammatory conditions or in tumors, HIFs are stabilized, dimerize with ARNT, and translocate 
to the nucleus to regulate transcription by binding to hypoxia response elements (HREs) in 
promoters of target genes (Fig. 1.1A). In addition to O2-dependent regulation, inflammation and 
direct HIF regulation are intimately linked. NF-κB, a master transcription factor in the 
                                                
1 This chapter represents published manuscript: Triner D and Shah YM. “Hypoxia-inducible 
factors: a central link between inflammation and cancer.” Journal of Clinical Investigation 2016. 
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inflammatory response, is a direct transcriptional regulator of Hif1a. In response to NF-κB-
activating stimuli, such as bacterial lipopolysaccharide (LPS), NF-κB directly increases Hif1a 
mRNA in macrophages (6). LPS-induced NF-κB can also increase HIF-1a protein stability by 
increasing intracellular ferritin, which sequesters the labile iron pool leading to decrease PHD 
activity (7). Independent of NF-κB, several cytokines and intermediate metabolites such as 
succinate can lead to HIF activation (8, 9). In macrophages, IL-4 and IL-13 selectively induce 
Hif2a mRNA (10). Several studies demonstrate that cytokine-induced ROS and specifically 
mitochondrial ROS directly activate HIF (11-13), and recently it was shown that mitochondrial 
membrane potential increases mitochondrial ROS to modulate HIF activation (14) (Fig. 1.1B). 
HIFs are critical drivers of cancer and regulate a wide variety of cellular processes 
including metabolism, cell cycle progression, angiogenesis, invasion/metastasis, and 
chemoresistance (15). HIF-1a and HIF-2a are highly expressed in a wide variety of solid 
tumors, including those of the colon, breast, lung, and pancreas (16). Although HIF-1a and HIF-
2a have several overlapping functions, distinct target genes and functions for HIF-1a and HIF-
2a are well-characterized (17) and highlighted in several tumor models (18). In renal cell 
carcinoma (RCC) that is deficient in VHL, which stabilizes HIF-1a and HIF-2a in normoxic 
conditions, HIF-1a has an anti-tumor role and decreases tumor growth by increasing expression 
of proapoptotic genes (19). HIF-2a is essential for RCC tumor growth and promotes tumor cell 
proliferation through augmented c-Myc activity (20). It is well known that hypoxia and HIF 
signaling play an important role in inflammatory responses and regulating the immune 
environment (21). However, the intersection of hypoxia, inflammation, and cancer is not well
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understood. Hypoxia can modulate the pro-tumor inflammatory response or anti-tumor-immune 
response in cancer.  
 
1.1 Inflammation and cancer  
It is widely recognized that inflammation plays an essential role in tumorigenesis and 
tumor progression. This paradigm dates back to Virchow, a 19th century pathologist whose 
observation of leukocytes in tumors led him to hypothesize that tumors originate in sites of 
chronic inflammation. The discovery of the first oncogene v-src in Rous sarcoma virus over a 
century ago led to decades of in-depth cancer genetic analysis and the discovery of numerous 
oncogenes and tumor-suppressors; however, studies of tumor-associated inflammation lagged 
behind. A renaissance over the last twenty years has uncovered a critical role for inflammation in 
the pathogenesis and progression of nearly all solid tumors and this knowledge has greatly 
changed the approach to current cancer treatments. The advent of immune-modulating therapies, 
such as immune checkpoint blockers for the treatment of advanced cancers, underscores the 
importance of understanding the specific function of inflammatory cells in cancer and is an 
exciting avenue for the discovery of novel therapeutic targets (22).    
 
Chronic inflammation-associated cancers 
As Virchow postulated, several chronic inflammatory diseases predispose the 
development of cancer. For example, Helicobacter pylori (H. pylori), a gram-negative bacterium, 
infects nearly 50% of the world’s population and is the major causative agent of chronic gastritis 
(23). Chronic gastritis associated with H. pylori is asymptomatic in the majority of infected 
individuals; however, this chronic gastritis represents a significant risk factor for the 
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development of gastric cancer, which occurs in 1-3% of H. pylori infections and is the third 
leading cause of cancer death worldwide (23). Similarly, chronic viral infections predispose to 
the development of cancer. Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections are 
key risk factors for development of hepatocellular carcinoma (HCC). For example, HCV infects 
more than 100 million people worldwide and HCC due to chronic hepatitis induced by HCV 
infection occurs in approximately 1-5% of infected individuals (24).  
One of the best-studied cancers from a genetic and inflammatory perspective is colon 
cancer. Chronic intestinal inflammation associated with inflammatory bowel disease (IBD), 
including Crohn’s Disease and ulcerative colitis, represents a significant risk factor for the 
development of colon cancer, termed colitis-associated colon cancers (CAC). More than 1 
million Americans suffer from IBD and 12-20% of patients will develop CAC within 30 years of 
developing IBD (25). The vast majority of colon cancers develop sporadically and proceed 
through a step-wise process from adenoma to invasive carcinoma (26). This process includes the 
acquisition of sequential mutations leading to the loss of adenomatous-polyposis coli (APC) 
tumor suppressor, activation of the oncogene KRAS, and loss of the TP53 tumor-suppressor (27). 
Interestingly, in colon cancers preceded by chronic inflammation due to IBD, the kinetics of the 
genetic alterations are different, as TP53 is lost early in disease progression and APC mutations 
are not as frequently observed compared to sporadic colon cancer (28, 29). These data suggest 





All solid tumors elicit an inflammatory response that is critical in the tumor 
microenvironment. The tumor-derived inflammatory response is essential for the recruitment of 
immune cells, tumor cell proliferation, survival, and angiogenesis (30). Tumors initiate these 
responses through several mechanisms including transcriptional regulation of inflammatory 
genes by proto-oncogenes (31, 32). It was recently demonstrated that defects in epithelial 
permeability elicited an inflammatory response through a microbiota-mediated mechanism in 
colon cancer (33).  
 
Pro- and anti-tumor immune responses 
In tumors, there is a mix of both innate and adaptive immune cells with anti- and pro-
tumor functions (1). Precise identification of immune cells found in tumor biopsies can serve as 
prognostic markers for clinical outcomes. Adaptive immune responses have been correlated with 
positive prognosis. Several distinct T-cell subsets reside within the tumor microenvironment, 
including cytotoxic anti-tumor CD8+ T-cells and subsets of CD4+ T-cells with both pro- and anti-
tumor functions. In colon cancer, decreased expression of CD8 as well as cytotoxic T-cell 
markers GZMB and CD45RO all correlated with disease recurrence (34). Furthermore, patients 
with high intratumoral expression of T-cell marker CD3 had improved disease-free survival 
compared to patients with low levels of CD3 (34). Recent meta-analysis studies have mapped the 
prognostic impact of twenty-two immune cell types on recurrence-free survival by analyzing 
expression signatures across more than 5,000 tumor samples (35). In general, these studies found 
a positive correlation of T-cells with recurrence-free survival and a negative correlation of 
several myeloid cell types such as neutrophils and macrophages (35). In ovarian cancer, 
increased CD8+/CD4+ T-cell ratio was associated with improved survival, whereas increased 
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CD4+ T-cells portend poor survival (36). Expression profiles associated with anti-tumor T-cell 
cytokines (IFNg) and effector molecules (granulysin and granzyme B) are also independent 
prognosticators of decreased early metastasis in colon cancer (37). These associations, however, 
do not highlight the complexity of the tumor immune environment. Many specific cell types 
have been associated with better or worse prognosis and the plasticity of immune cells can 
confer both pro- and anti-tumor functions, which we will review in depth.  
 
1.2 Hypoxia and epithelial-elicited tumor inflammatory response 
Historically it was believed that the major function of epithelial surfaces, such as the skin 
or the intestinal epithelium, was to serve as a physical barrier separating the external 
environment from the underlying immune cells. It is now evident that epithelial surfaces play an 
active role in innate immunity and shape the underlying immune environment and inflammatory 
response (38, 39). This is also the case in epithelial-derived cancers. Colon tumor cell secretion 
of the C-C family chemokine, CCL2, was essential for tumorigenesis through recruitment and 
activation of pro-tumorigenic myeloid cells (40). PTX3 is a tumor suppressor that activates 
Complement-mediated anti-tumor immunity and is epigenetically silenced due to methylation in 
colon tumors (41). Recent studies in colon cancer have further highlighted the contribution of 
epithelial and stromal gene expression in patient-derived colon cancer xenograft models (42). In 
these studies the epithelial and stromal gene expression was readily delineated by analyzing 
tumor expression of human or mouse transcripts. Analysis of genes with a greater than 50% 
difference in expression between the epithelium and the stroma showed that several cytokines 
and chemokines are directly expressed by the tumor epithelium (42). These results demonstrate 
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that tumor epithelial cells play an active role in regulating the inflammatory response, which may 
impact tumorigenesis.  
Several lines of evidence suggest that intra-tumoral hypoxia and HIFs plays an essential 
role in sculpting the tumor immune environment in several epithelial-derived tumors. For 
example, in a Kras-driven mouse model of non-small cell lung cancer, loss of HIF-2a increased 
tumor burden and tumor cell proliferation; however, loss of HIF-1a had no effect on 
tumorigenesis (43). Tumors lacking HIF-2a also displayed increased infiltration of CD45+ 
immune cells, specifically Gr-1+ granulocytic cells, suggesting that HIF-2a repression of 
granulocytic cell infiltration is in part responsible for its anti-tumor effects (43). Hypoxia and 
HIF stabilization is also a key feature of pancreatic ductal adenocarcinoma (PDAC) (16). PDAC 
development occurs in a step-wise manner and is preceded by precursor lesions termed 
pancreatic intraepithelial neoplasias (PanINs) (44). In contrast to studies showing decreased 
PanIN progression following pancreatic-specific disruption of HIF-2a (45), deletion of HIF-1a 
in a murine model of Kras-initiated PDAC significantly enhanced PanIN progression and 
increased tumor cell proliferation (46). Loss of HIF-1a correlated with increased pancreata B 
cell infiltration and antibody-mediated depletion of B cells reversed the increased PanIN 
progression (46). Hypoxic inflammation is also important in colon tumorigenesis and both HIF-
1a and HIF-2a are overexpressed in colon tumors (16). Using the Apcmin/+ model of intestinal 
tumorigenesis, intestine-specific disruption of the tumor suppressor Vhl significantly increased 
colon tumorigenesis and adenoma-to-carcinoma progression (47). The increase in colon 
tumorigenesis was HIF-2a-dependent, as double disruption of Vhl as well as Hif2a ameliorated 
the effect (47). HIF-2a-mediated inflammatory responses are essential in colon tumorigenesis. 
Epithelial HIF-2a regulates expression of the pro-inflammatory meditator Tnfa (48).  TNFa has 
	 8 
a crucial role in the progression of cancer and inhibiting TNFa decreases growth in several 
mouse models of cancer (49, 50). HIF-2a-induced inflammation was found to be critical to 
tumor progression, as treatment with the anti-inflammatory drug nimesulide significantly 
reduced HIF-2a-driven colon tumorigenesis. (48). These previous studies of HIF-2a in colon 
cancer have been examined in sporadic colon tumor models. Although HIF-2a has a prominent 
role in acute colitis, its function in colitis-associated colon cancer has yet to be investigated. 
 Intestine-specific overexpression of HIF-1a does not enhance tumorigenesis in colon 
cancer (51). The precise factors which govern the divergent functions of HIF-1a and HIF-2a in 
colon cancer are currently not well understood. It has been proposed that HIF target gene 
specificity are dependent upon interactions with cofactors. Interestingly, we have identified a 
critical transcription factor, Myc-associated zinc finger (MAZ), as an essential cofactor 
interacting with HIF-2a and driving HIF-2a-dependent transcription of inflammatory target 
genes Tnfa in colitis (48). The work in this thesis expands upon these previous studies to suggest 
that MAZ is essential in the regulation of HIF-2a-dependent Cxcl1 expression in inflammation-
induced colon cancer (52). These studies suggest that tumor HIFs have the potential to modulate 
tumor-associated inflammation to regulate tumor growth and progression. 
 
1.4 Hypoxia and immune cell recruitment 
Tumors are highly infiltrated by cells of both the innate and adaptive immune systems. 
This infiltration is in part mediated by tumor-derived secretion of a host of cytokines and 
chemokines (Fig. 1.2A). HIF-induced secretion of tumor-derived factors can modulate immune 
cell recruitment to aid in tumor growth, which we will review in detail by immune cell subtype 
(Table 1.1).  
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T-cells 
CD4+ T-cells can be differentiated into several different helper T (Th) cell types. Th1 and 
Th2 CD4+ T-cells are the classical types of Th cells that play an important role in the 
inflammatory response to infection and cancer (53). Th1 and Th2 cells promote anti-tumor 
immunity by cytotoxic lymphocyte activation and humoral-mediated immune responses, 
respectively (53). In addition to the classic Th1 and Th2 T-cell effector populations, other 
subsets of T-cells have been found to have an important role in cancer. For example, Th17 cells 
are a recently identified subset of IL-17-expressing CD4+ T-cells that are highly prevalent in 
tumors and have a controversial role in tumor progression. IL-6 and TGF-β collaboratively 
promote Th17 differentiation (54) and Th17 differentiation by these cytokines is dependent on 
HIF-1a (55). Th17 cells have both anti- and pro-tumor functions. In a melanoma model, Th17 
cells showed more potent tumor eradication than Th1 cells (56). However, in other models, Th17 
cells promote tumor growth through angiogenic and immune suppressive effector functions (57, 
58).  
Immunosuppressive regulatory T-cells (Tregs) are frequently increased in cancers (59). 
Tregs are CD4+ and defined by expression of forkhead box transcription factor 3 (FoxP3). Tregs 
have been largely shown to promote tumorigenesis through suppression of anti-tumor CD4+ and 
CD8+ T-cell-mediated immune responses by secreting immunosuppressive molecules such as IL-
10 and TGF-β; removal of Tregs improves anti-tumor immunity (60-62). Primary tumor hypoxia 
regulated recruitment of CCR10+CD4+FoxP3+ immunosuppressive Tregs in a model of ovarian 
cancer, which increased immune tolerance and angiogenesis through VEGF secretion (63). This 
effect was regulated by hypoxia-induced excretion of the chemokine CCL28, which was 
dependent upon HIF-1a and to a lesser extent HIF-2a (63).   
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B-cells 
The precise role for B-cells in tumor progression is controversial and they may function 
to enhance or inhibit anti-tumor immune responses. B-cells can be directly cytotoxic to tumors 
and promote anti-tumor T-cell responses (64). However, B-cells have also been shown to inhibit 
the function of anti-tumor T-cells, as depletion of B-cells increases anti-tumor immunity, 
suggesting context specific roles for B-cells in anti-tumor immunity (65). In pancreatic cancer, as 
detailed above, HIF-1a in epithelial cells decreased tumor growth by attenuating expression of 
B-cell-recruiting chemokines, resulting in decreased B-cell infiltration into the tumors (46). 
Myeloid Derived Suppressor Cells  
Hypoxia also regulates tumor recruitment of immune suppressive myeloid cells. Myeloid 
cells include monocyte/macrophages, neutrophils, eosinophils, basophils, mast cells, and 
dendritic cells. During infection or in cancers, immature myeloid cells closely related to 
neutrophils and monocytes can be detected in circulation. These cells, termed myeloid derived 
suppressor cells (MDSCs), dampen immune responses to infection and are an important 
suppressor of anti-tumor immunity. (66). MDSCs promote tumor growth through suppression of 
both NK- and T-cell-mediated anti-tumor immune responses (66). This is through multiple 
mechanisms including arginine metabolism via increased expression of arginase 1 (ARG1), 
which converts the available L-arginine pool to urea and L-ornithine. Additionally, MDSCs 
mediate nitration of tyrosine residues in the T-cell receptor (TCR) and CD8, which decreases the 
function of these proteins (67-69). The function of MDSCs is well described in the 
azoxymethane (AOM) and dextran sulfate sodium (DSS) model of CAC. Mice with CXCR2-
deficient bone marrow have significantly reduced MDSC homing to colon tumors and decreased 
colon tumorigenesis (70). Tumor-specific hypoxia increased recruitment of MDSCs 
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(CD11b+/Ly6C-/Ly6G+) to the lung premetastatic niche to promote metastasis. This effect was 
partly regulated through inhibition of NK cell-mediated cytoxicity (71). In head and neck 
squamous cell carcinoma, hypoxia increased recruitment of MDSCs in a process that was 
dependent upon both HIF-1a and HIF-2a induction of the potent chemoattractant migration 
inhibitory factor (MIF) (72). 
Tumor–associated macrophages  
The best-characterized immune cell type in the tumor microenvironment is tumor-
associated macrophages (TAMs). TAMs are highly prevalent in the tumor microenvironment and 
can be polarized into anti-tumor M1 or pro-tumor/immunosuppressive M2 phenotypes (73). M2 
TAMs regulate tumor angiogenesis and are an important source of VEGF (74). TAMs directly 
promote tumor growth via direct secretion of cytokines such as IL-6, which induces tumor-cell 
STAT3 signaling to promote growth and stem cell expansion (75), and have been directly linked 
to tumor invasion and metastasis (76, 77). TAMs inhibit anti-tumor immune responses through 
secretion of immune suppressive cytokines such as IL-10 and TGF-β (78). ARG1 expression in 
human monocytes and macrophages is controversial and has not been definitively shown in 
tumors (79). In rodents, however, there is clear evidence showing TAM expression of 
immunesuppressive ARG1 (80). TAMs reside in largely avascular and hypoxic regions of 
tumors (81). Tumor hypoxia is a potent driver of TAM recruitment, and induces the secretion of 
chemoattracants such as oncostatin M and eotaxin (82). Moreover, tumor HIF-1a directly 
induces recruitment of monocyte/macrophage cells through regulation of stromal-derived factor 
1a (SDF1a/CXCL12) expression (83). Expression of the SDF1a/CXCL12 receptor, CXCR4, is 
also regulated by hypoxia in TAMs (84). TAM polarization into a pro-tumorigenic M2 
phenotype can be directly regulated by tumor hypoxia. Tumor-derived lactic acid is induced by 
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hypoxia in a HIF-1a-dependent manner and promotes M2 macrophage polarization and regulates 
expression of M2 TAM markers ARG1 and VEGF (85). Importantly, blockade of TAM 
recruitment to hypoxic tumor areas and trapping TAMs in normoxic tumor microenvironments 
through loss of the Semaphorin 3A receptor Nrp1 decreased tumor growth through blunted 
angiogenesis and increased anti-tumor T-cell responses showing that hypoxia-induced 
localization of macrophages causes a switch from anti- to pro-tumor phenotypes. (86).  
Neutrophils  
A close relationship of neutrophils (polymorphonuclear neutrophils [PMNs]) and tissue 
hypoxia has been recently shown. The reactive oxygen burst that is critical for neutrophil 
function can affect local tissue oxygenation (87).  Although PMNs are highly prevalent in most 
solid tumor types, the specific role for PMNs is not completely understood. PMNs are highly 
plastic and can be differentiated into anti-tumor (N1) and pro-tumor (N2) phenotypes (88). Pro-
tumor PMNs regulate tumor growth through secretion of cytokines, ROS production, generation 
of matrix degrading enzymes, and angiogenesis (89). PMNs have also been shown to play an 
essential role in promoting metastasis in a murine breast cancer model (90). The specific role for 
PMNs in colon cancer has largely suggested a pro-tumorigenic role. However, PMNs expressing 
the hepatocyte growth factor (HGF) receptor, c-MET, were found to be anti-tumorigenic in 
mouse models of colon cancer (91). It is not currently well understood the contribution of PMNs 
to the initiation of most cancers, particularly colon cancer. Interestingly, PMNs have recently 
been demonstrated to reside in hypoxic tumor regions in epithelial uterine tumors and this effect 
was regulated by hypoxic tumor cell expression of PMN chemoattractants such as CXCL5 (92).  
 
1.5 Hypoxic regulation of tumor immune cell function. 
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Hypoxia is a hallmark of tumors and most infiltrating immune cells function in the 
hypoxic tumor environment. Immune cell expression of HIF-1a and HIF-2a regulates effector 
function (Table 1.1) (93). Tumor hypoxia has an essential role in regulating tumor inflammatory 
cell functions in addition to regulating immune cell recruitment (Fig. 1.2B). TAMs express both 
HIF-1a and HIF-2a (16, 94). TAM HIF-2a expression is highly correlated with tumor 
vascularity and tumor grade (95). Macrophage HIF-2a is critical in regulating macrophage 
inflammatory cytokine expression following LPS and IFNg challenge (96). Importantly, 
macrophage loss of HIF-2a impaired TAM infiltration of tumors and decreased tumor burden in 
murine models of HCC and CAC (96). TAM HIF-1a has also been shown to play an important 
role in TAM-mediated suppression of tumor-associated T-cells (97). TAMs cultured under 
hypoxic conditions exhibited increased suppression of T-cells in a HIF-1a-dependent manner 
without affecting TAM recruitment or polarization (97). Furthermore, tumor hypoxia regulates 
TAM expression of VEGF, suggesting a role for hypoxic TAMs in angiogenesis (98).  
Hypoxia and HIF-1a have an important role in regulating tumor-associated MDSC function. 
MDSCs cultured with the hypoxia-mimetic desferroxamine (DFO) robustly suppress T-cell 
proliferation and loss of HIF-1a decreases MDSC-mediated T-cell suppression (99). Hypoxia 
induces MDSC expression of miR-210 in a HIF-1a-dependent manner and miR-210 promotes 
MDSC-mediated T-cell suppression by increasing ARG1 expression and NO synthesis (100). 
Notably, HIF-1a increases mRNA expression of the immune checkpoint receptor programmed 
death ligand-1 (Pdl1) in MDSCs, which is essential for their T-cell immunosuppressive ability 
(101). MDSCs also have the capacity to differentiate into TAMs and HIF-1a is a critical 
mediator of this plasticity (99).  
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The role of PMN HIF-1a and HIF-2a in the tumor microenvironment are not well 
understood. However, it has been shown that PMN HIF-1a is an essential PMN survival factor 
through an NF-κB-dependent signaling loop (102). Constitutive HIF-2a activation increases 
PMN inflammatory responses and loss of HIF-2a increases susceptibility to apoptosis (103).  
Dendritic cells (DCs) are antigen-presenting cells that are central regulators of the adaptive 
immune response. DCs can sample tumor antigens and activate CD8+ T-cell responses and are 
currently in clinical trials as a vaccination strategy to prime anti-tumor immune responses (104). 
DCs function is directly regulated by hypoxia and HIFs. Activated dendritic cells increase 
expression of costimulatory molecules and T-cell activation in response to TLR stimulation 
when cultured in hypoxia in a HIF-1a-dependent manner (105). Alternatively, it has been 
suggested that hypoxic treated immature DCs have impaired antigen uptake and T-cell activation 
(106, 107). Moreover, hypoxia inhibits DC maturation and T-cell activation but simultaneously 
increases DC inflammatory cytokine secretion (108). Although it is unclear, this dichotomy may 
be due to maturation state of DCs. Further work is needed to address more precisely DC HIF-1a 
and HIF-2a in the progression of cancer and anti-tumor immune responses. 
Tumor hypoxia increases T-cell expression of FoxP3 through tumor secretion of TGF-β 
in vitro, suggesting hypoxic tumor cells can induce Treg differentiation (109). Tregs are more 
efficiently activated systemically than within the tumor microenvironment (110) and tumor 
secretion of cytokines such as TGF-β may be a critical source of systemic Treg activation and 
infiltration into tumors. CD4+ T-cell HIF-1a directly targets the Foxp3 promoter and increases 
immunosuppressive Treg cell production and function (111, 112). Loss of HIF-1a in Tregs 
decreased their immune-suppressive function (111). The specific role for hypoxia signaling in 
anti-tumor CD4+ and CD8+ T-cell responses is not completely clear. T-cell HIF-1a represses T-
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cell inflammatory responses, as depletion of HIF-1a significantly enhanced IFNg and IL-2 
production (113). However, other studies have shown that hypoxia signaling has the capacity to 
increase CD8+ T-cell function, as Vhl depletion in CD8+ T-cells increased T-cell effector 
responses and decreased tumor growth in a model of melanoma (114). Additionally, HIF-1a 
regulates expression of T-cell CD137, which augments anti-tumor immunity upon antibody-
mediated activation (115). More work is needed to further understand the specific roles of 
hypoxia and HIFs in anti-tumoral T-cell responses. In addition, hypoxia has cell intrinsic roles in 
CTLs and NK, and NKT cells, which have not been completely assessed in tumor biology. 
 
1.6 Hypoxia, stromal cells, & inflammation  
In addition to immune cells, the tumor microenvironment is also made up of vascular 
endothelial cells, fibroblasts, and pericytes, collectively known as the stroma. In tumor 
endothelial cells, depletion of HIF-1a reduced tumor metastasis, whereas depletion of 
endothelial HIF-2a increased tumor metastasis (116). This dichotomy was due to differential 
regulation of nitric oxide (NO) homeostasis by HIF-1a and HIF-2a. HIF-1a regulates 
expression of inducible nitric oxide synthase (iNOS), which catalyzes the conversion of l-
arginine to NO. iNOS was also an essential regulator of VEGF expression to promote increased 
tumor vascularity (116). Myeloid cell and mesenchymal stem cell NO production has been 
implicated in decreasing T-cell cytotoxicity; thus, it is possible that endothelial cell NO has a 
similar function (117-119). On the other hand, HIF-2a regulates expression of ARG1, which 
metabolizes l-arginine. ARG1 expression in immune cells is a potent suppressor of anti-tumor T-
cells. Future studies should determine if endothelial ARG1 also has an immune-suppressive role 
in the tumor microenvironment.  
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Fibroblasts are frequently recruited to tumors and make up a variable proportion of the 
tumor mass (120). Cancer-associated fibroblasts (CAFs) have a largely pro-tumor role and 
promote angiogenesis through VEGF secretion and increase invasion/metastasis through 
secretion of extracellular matrix-degrading matrix metalloproteinase enzymes (120-122). 
Conditional loss of CAF HIF-1a by Fsp1-Cre expression decreased TAMs in mouse mammary 
tumors suggesting that CAF HIF-1a is important for TAMs tumor infiltration (123). These 
results demonstrate that stromal cell HIF signaling can also modulate the microenvironment of 
tumors. However, the specific role for HIFs in the tumor endothelial cells and CAFs and the 
significance of this relationship to tumor inflammatory responses has not been fully elucidated. 
 
1.7 Hypoxia and intratumor heterogeneity  
Tumor growth is an evolving process that leads to an accumulation of genetic alterations. 
This evolutionary process in tumors leads to substantial spatial variation in which genetically 
distinct subclonal populations of cancer cells exist (124). Although not completely clear at 
present, a few studies have demonstrated that intratumor heterogeneity is an independent risk 
factor for poor survival in several tumor types (125). Mechanisms which drive regional 
heterogeneity in tumors are poorly described. Hypoxia-induced immune cell recruitment and 
modulation could be an important process in driving regional selective pressures in tumors. More 
work is needed to elucidate mechanisms by which hypoxia and immune cells establish 
microenvironments leading to intratumor heterogeneity. Although, through enhanced imaging it 
is clear that distinct subpopulation of hypoxic cells are observed in tumors (126-128). Through 
histopathologcal and molecular analysis it is clear that distinct tumor regions have different 
inflammatory infiltrates and this can be modulated by intratumoral hypoxia (129, 130).  
	 17 
1.8 Perspectives  
Hypoxia is an important microenvironmental feature in solid tumors and is essential for 
tumor growth. HIF-1a and HIF-2a have been extensively studied in regulating tumor glucose 
metabolism, angiogenesis, cell survival, proliferation and migration. Research in the past two 
decades has established an essential role for pro-tumor inflammatory response or anti-tumor-
immune response in the growth of most solid tumors and with this increased focus, Hanahan and 
Weinberg’s “hallmarks of cancer” were recently updated to include tumor inflammation and 
immune evasion as a major enabling factor in cancer progression (131). It is becoming clear that 
hypoxia is central to regulating the inflammatory response in tumors.  The work presented in this 
thesis clearly delineates a novel role for epithelial HIF-2a as a regulator of the colon tumor 
inflammatory microenvironment in colon cancer through recruitment of PMNs (Chapter 2). Our 
work also challenges the role for PMNs in colon cancer and suggest that PMNs while important 
for promoting growth and progression of established tumors, restrict the earliest stages of 
tumorigenesis (Chapter 3). Lastly, we have identified Myc-associated zinc finger (MAZ), a 
previously described HIF-2a interacting protein, as having a novel role in the inflammatory 
progression in colitis and colon cancer and regulation of oncogenic signaling pathways (Chapter 
4). Future studies should be directed towards a better understanding of the precise molecular 
mechanisms by which hypoxia and PMNs alters the balance between growth-promoting 
inflammation and the anti-tumor immune response, which may lead to better use of existing 
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Figure 1.1. Activation of HIFs by hypoxia and inflammation. (A) HIF-a subunits are 
regulated by post-translational hydroxylation of two specific proline residues by PHD enzymes 
in normoxic conditions. This leads to VHL-mediated proteasomal degradation. As O2 
concentration drops or mitochondrial ROS production increases, HIF-α are stabilized, dimerize 
with ARNT, translocate to the nucleus and bind to HRE sequences in target genes. (B) HIFs are 
activated by inflammation through cytokine-induced Hif2a expression, NF-κB-mediated 
transcription of Hif1a, NF-κB-dependent ferritin iron sequestration, cytokine-mediated 














Figure 1.2. Hypoxic activation of tumor-promoting inflammatory responses. (A) As O2-
concentration declines in tumors, hypoxia directed secretion of cytokines and chemokines such 
as CXCL5, CXCL12, CCL28, and MIF to recruits pro-tumor immune cells including Tregs, 
TAMs, neutrophils, B cells, and MDSCs. (B) Recruited immune cells reside in hypoxic areas of 
tumors and hypoxia and HIFs regulate inflammatory cell effector functions to promote tumor 
growth. This includes suppression of anti-tumor immune responses, ROS production, 




Table 1.1: Regulation of immune cell effector functions by HIF-1α and HIF-2α 
	
Immune Cell Recruitment 
 
HIF-1α HIF-2α 
TAM Promotes chemoattraction via SDF-1α/CXCL12 expression (83) Not Known 
DC Not known Not known 
PMN Not Known Represses GR-1+ granulocyte recruitment to lung tumors (43) 
MDSC Increased recruitment to HNSCC through MIF secretion (72) 
Increased recruitment to HNSCC 
through MIF secretion (72) 
Treg Regulates CCL28 expression in ovarian cancer (63) Not known 
Th17 Not known Not known 
CD4 Not known Not known 
B cell Repress B cell infiltration into pancreatic tumors (46) Not known 
	
Immune Cell Effector Function 
 
HIF-1α HIF-2α 
TAM T-cell suppression (97) Essential pro-tumor function and inflammatory responses (96) 
DC Not known Not Known 
PMN Decrease apoptosis (102) Regulates PMN-mediated inflammatory responses (103) 
MDSC T-cell suppression (99); Pdl1 expression (101) Not known 
Treg Regulates Foxp3 expression (111); essential for immunesuppression Not Known 
Th17 Essential for Th17 differentiation (55) Not Known 
CD4 
Represses cytokine secretion (113); 
regulates CD137 to augment anti-tumor 
immunity (115) 
Not Known 





Table 1.2 Mouse models  
Genotype Chapter Description  
VhlF/F 2 Villin-Cre expressing, Vhl WT 
VhlΔIE 2 Villin-Cre expressing, Vhl floxed 
Hif-1αF/F 2 Villin-Cre expressing, Hif-1α WT 
Hif-1αΔIE 2 Villin-Cre expressing, Hif-1α floxed 
Hif-2αF/F  2 Villin-Cre expressing, Hif-2α WT 
Hif-2αΔIE 2 Villin-Cre expressing, Hif-2α floxed 
Hif-2αLSL 2 Villin-Cre expressing, Hif-2α overexpression 
Hif-2α+/+  2 Villin-Cre expressing, Hif-2α WT 
Hif-2α+/+/ApcMin/+  2 Villin-Cre expressing, Hif-2α WT, ApcMin/+  
Hif-2αΔIE/ApcMin/+  2 Villin-Cre expressing, Hif-2α floxed, ApcMin/+  
Hif-2α+/+/ApcMin/+  2 Villin-Cre expressing, Hif-2α WT, ApcMin/+  
Hif-2αLSL/ApcMin/+  2 Villin-Cre expressing, Hif-2α overexpression, ApcMin/+  
LysMCre;Mcl1wt/wt 3 LysozymeM-Cre expressing, Mcl1 WT 
LysMCre;Mcl1fl/wt  3 LysozymeM-Cre expressing, Mcl1 Het 
LysMCre;Mcl1fl/fl  3 LysozymeM-Cre expressing, Mcl1 floxed 
Mrp8Cre;Mcl1wt/wt   3 Mrp8-Cre expressing, Mcl1 WT 
Mrp8Cre;Mcl1fl/fl   3 Mrp8-Cre expressing, Mcl1 floxed 
Cdx2-CreERT2;Apcfl/fl  3 Tamoxifen inducible Cdx2-CreERT2, Apc floxed 















Epithelial Hypoxia-Inducible Factor 2a Facilitates the Progression of Colon Tumors 
through Recruiting Neutrophils 
 
Abstract 
Inflammation is a significant risk factor for colon cancer. Recent work has demonstrated 
essential roles for several infiltrating immune populations in the metaplastic progression 
following inflammation. Hypoxia and stabilization of hypoxia-inducible factors (HIFs) are 
hallmark features of inflammation and solid tumors. Previously, we demonstrated an important 
role for tumor epithelial HIF-2a in colon tumors, however, the function of epithelial HIF-2a as a 
critical link in the progression of inflammation to cancer has not been elucidated. In colitis-
associated colon cancer models, epithelial HIF-2a was essential in tumor growth. Concurrently, 
epithelial disruption of HIF-2a significantly decreased neutrophils in the colon tumor 
microenvironment. Intestinal epithelial HIF-2a overexpressing mice demonstrated that 
neutrophil recruitment was a direct response to increased epithelial HIF-2α signaling. RNA-seq 
analysis from HIF-2a overexpressing mice in conjunction with data mining from The Cancer  
                                                
2 This chapter represents published manuscript: Triner D, Xue X, Schwartz AJ, Jung I, Colacino 
JA, and Shah YM. “Epithelial Hypoxia-Inducible Factor 2a Facilitates the Progression of Colon 
Tumors Through Recruiting Neutrophils.” Molecular and Cellular Biology 2017. 
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Genome Atlas identified the neutrophil chemokine CXCL1 gene was highly upregulated in colon 
tumor epithelium in a HIF-2a dependent manner. Using selective peptide inhibitors of the 
CXCL1-CXCR2 signaling axis identified HIF-2a-dependent neutrophil recruitment is an 
essential mechanism to increase colon carcinogenesis. These studies demonstrate that HIF-2a is 
a novel regulator of neutrophil recruitment to colon tumors and is essential in shaping the pro-
tumorigenic inflammatory microenvironment in colon cancer. 
 
Introduction 
Colon cancer remains a significant public health concern and is the second-leading cause 
of cancer-associated deaths in the United States (1). Patients with chronic inflammation 
associated with inflammatory bowel disease (IBD), comprising of ulcerative colitis and Crohn’s 
Disease, are at an increased lifetime risk of developing colon cancer; these tumors are termed 
colitis-associated cancers (CAC) (2). The genetic changes of sporadic colon cancer have been 
well defined, and a comprehensive genetic analysis of CAC was recently reported (3). In contrast 
to sporadic colon cancer, CAC are associated with early loss of the TP53 tumor suppressor and 
less frequent inactivation of adenomatous polyposis coli (APC) (4). Inflammation is an important 
component in the progression of sporadic cancer and the inflammatory response is essential in 
the initiation and progression of CAC (5). The precise mechanisms that initiate the pro-
tumorigenic response following inflammation remain unknown.  
Hypoxia is a characteristic feature of IBD and nearly all solid tumors including those of 
the colon (6). Hypoxia promotes activation of the hypoxia-inducible factors (HIFs). HIFs consist 
of a heterodimer of an O2-labile α-subunit (HIF-1α, HIF-2α, and HIF-3α) and an O2-stable β-
subunit (ARNT) (7). HIFs regulate transcription of target genes that mediate cellular responses to 
	 33 
hypoxic microenvironments. HIFs are also essential factors promoting tumorigenesis and 
regulate several neoplastic processes including growth, evasion of apoptosis, and 
chemoresistance (8). Previously, we have shown that overexpression of intestinal epithelial HIF-
2α, but not HIF-1α, can increase colon tumor progression in mouse models of sporadic colon 
tumorigenesis (9, 10). The essential role and mechanisms by which HIF-2α regulates CAC have 
not been defined.  
Inflammation is a critical component of the colon tumor microenvironment and colon 
tumors are highly infiltrated with cells of both the innate and adaptive immune systems (5). 
Neutrophils are granulocytic myeloid cells with a critical role in the innate immune response (11) 
and are highly prevalent in colon tumor microenvironment (12), but the function of neutrophils 
in the initiation and progression of cancer remains controversial. Previous studies have shown 
neutrophils can be polarized into anti-tumorigenic (N1) and pro-tumorigenic (N2) (13). N2 
neutrophils promote tumorigenesis through suppression of anti-tumor immunity, activation of 
oncogenic signaling through secretion of neutrophil elastase, and activation of angiogenesis (14-
16). On the other hand, anti-tumorigenic N1 neutrophils can suppress tumorigenesis through 
direct tumor cytotoxicity and activation of anti-tumor immunity (17). Neutrophil recruitment into 
tumors can be regulated by tumor-derived secretion of a variety of chemokines and cytokines. 
However, the precise mechanisms mediating recruitment of neutrophils into colon tumors are not 
well defined.  
In the present study, we show that the colon epithelial hypoxic response through 
activation of HIF-2a is essential in colon tumorigenesis in mouse models of CAC. 
Mechanistically, intestinal epithelial HIF-2a is a critical mediator of neutrophil recruitment to 
colon tumors through direct transcriptional regulation of the potent neutrophil chemokine, 
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CXCL1, in colon tumors. Taken together, these studies provide novel insights into hypoxic 
inflammatory responses in the progression of colon tumors and suggest rationale for the targeting 






VhlF/F, VhlΔIE, Hif-1αΔIE, Hif-1αF/F, Hif-2αΔIE, Hif-2αF/F, Hif-2αLSL, Hif-2α+/+ mice were 
previously described (10, 18). For all experiments, male and female mice aged 6- to 8-weeks 
were used. To evaluate HIF-2α in colon tumorigenesis, Hif-2αΔIE and Hif-2αLSL were crossed to 
ApcMin/+. To induce colon tumorigenesis in Hif-2αΔIE/ApcMin/+, animals were treated with 2% 
DSS in their drinking water for 5 days then placed back on regular drinking water for 28 days. 
For AOM/DSS experiments, animals were injected I.P. with azoxymethane (10mg/kg) then 
cycled on 1.5% DSS in their drinking water for five days followed by regular drinking water for 
2-weeks for three cycles. For the CXCR2 pepducin experiment, following the third cycle, VhlΔIE 
mice were treated with CXCR2 pepducin (pal-RTLFKAMGQKHR) or control peptide (pal-
TRFLAKMHQGHKR) (Genscript) for 35 consecutive days (s.c. 2.5mg/kg) (19). All animal 
studies were carried out in accordance with Institute of Laboratory Animal Resources guidelines 




Single cell suspensions from fresh normal colon or colon tumor tissue were prepared by 
finely mincing tissue and incubating with Collagenase Type II (Sigma-Aldrich) (1mg/ml) at 37ο 
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C for 1-hour then passed through a 40!m cell strainer. Single-cell suspensions were stained in 
HBSS in 2% FBS with eFluor780-conjugated anti-CD45 (eBioscience), PE-conjugated anti-
Ly6G (BD), APC-conjugated anti-Cd11b (eBioscience), and eFluor450-conjugated anti-F4/80 
(eBioscience). Flow cytometry was performed using an LSRFortessa (BD). Flow cytometry data 
was analyzed using FlowJo software.  
 
Neutrophil isolation and transwell assay  
Bone marrow cells were suspended in HBSS buffer supplemented with 20mM HEPES 
and 0.5% FBS. The isolated bone marrow was disaggregated through 18G needle. To lyse the 
residual RBCs, 0.2% NaCl was added to the cells for 45 seconds and the reaction was stopped 
with 1.2% NaCl. The cells were resuspended in HBSS buffer and carefully layered over 62% 
Percoll. The centrifugation was performed at 2,200 rpm for 30 minutes. The cell pellet was 
washed twice with PBS and used for antibody staining to confirm purity. The antibodies used 
were PerCP-Cy5.5-conjugated anti-CD45 (ebioscience), APC-conjugated anti-CD11b 
(ebioscience), and PE-conjugated anti-Ly6G (BD) and eFluor450-conjugated anti-F4/80 
(ebioscience) antibodies. Debris (FSC-A/SSC-A) and doublets (FSC-A/FSC-H) were excluded 
and CD45+ cells were then sub-gated on CD11b+ and Ly6G+ neutrophils. The numbers indicate 
the relative percentages of each population. For transwell assay, 1x106 neutrophils were cultured 
in the top well in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS 
and 1% anti-biotic/anti-mycotic and fresh colon explants were plated in the bottom well. 
Migration was assessed at 2-hours after plating. 
 
Isolation of colon epithelial cells and intraepithelial lymphocytes 
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Isolation of colon epithelial cells (CECs) and intraepithelial lymphocytes was performed 
as previously described (10). Briefly, colon tissue was isolated and incubated with EDTA and 
DTT in Hanks’ balanced salt solution (HBSS). To separate CECs and IELs, the tissue was 
passed through a cell strainer and exposed to a 67%:44% Percoll gradient separation. CECs were 
collected from the top and IELs were collected at the interface of the Percoll gradient.  
 
Histology 
Colon tissue and tumors were excised, fixed, sectioned and stained as previously 
described (9). Antibodies for immunofluorescence were as follows: BrdU (eBioscience) Ki67 
(1:100) (Vector Labs), Ly6G (1:100) (BD), and Alexa Fluor® 488 goat anti-mouse IgG (1:500) 
(Molecular Probes Inc).  
 
RNA isolation, qPCR analysis and high throughput RNA sequencing (RNA-seq) 
RNA was isolated and qPCR analysis was conducted as previously described (9). Primers 
are listed in Table 2.1. RNA sequencing libraries were prepared using the TruSeq RNA Library 
Prep Kit v2 (Illumina) following the manufacturer’s recommended protocol. Libraries were 
sequenced using single end 50 cycle reads on a HiSeq 2500 sequencer (Illumina) at the 
University of Michigan DNA Sequencing Core Facility. 
 
RNA-seq data analysis 
Raw sequencing read quality was assessed utilizing FastQC. Reads were aligned to the 
reference mouse transcriptome (UCSC mm10) using Bowtie v 2.1.0.0 (20) and TopHat v 2.0.9 
(21). Default parameters were used for the alignment, with the exception of ““--b2-very-
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sensitive”, “--no-coverage-search” and “--no-novel-juncs”. Mate inner pair distances were 
estimated by TopHat, and these values were used in the alignment. Expression quantification and 
differential expression analysis between Hif-2αLSL, and Hif-2α+/+ mice was conducted using 
CuffDiff v2.1.1 (22) using the parameter settings “--multi-read-correct”, “--compatible-hits-
norm”, and “--upper-quartile –norm” for normalization of expression calculations across 
samples. For the CuffDiff analysis, we used UCSC mm10.fa as the reference genome and UCSC 
mm10.gtf as the reference transcriptome. Genes were considered differentially expressed 
between conditions at a false discovery rate adjusted p-value < 0.05 (23). 
 
Pathway analyses 
A directional analysis was conducted on all genes by including p-value of the differential 
expression test as a measure of effect size and log2 fold difference in expression as a measure of 
effect direction using iPathways (Advaita). Differentially expressed pathways were identified 
utilizing PANTHER Classification System (http://pantherdb.org/). KEGG biological pathways 
and Gene Ontology biological processes were considered differentially expressed at a p-value 
<0.05. 
 
CXCL1 luciferase reporter activity 
The Cxcl1 promoter was cloned using primers listed in Table 2.1. Cxcl1 promoter 
fragments were subsequently cloned into pGL3-basic vector (Promega). Luciferase activity 
assays were performed as previously described and normalized to β-galactosidase activity (24). 




Enteroids were generated from colon tissue from mice with inducible, colon epithelial 
specific deletion of Apc, activation Kras, and loss of Tp53 (Cdx2CreER;Apcfl/fl;KrasG12V;Tp53fl/fl). 
Mice were sacrificed and the colon was cut open longitudinally. All plasticware was pre-coated 
with 0.1% BSA and all steps were carried out on ice unless specified. The tissue was incubated 
for 15 minutes at room temperature in 2.5 µg/mL amphotericin B (Fungizone, ThermoFisher) in 
Dulbecco's Phosphate-Buffered Saline containing 25 µg/mL gentamicin (Gibco) and 50 µg/mL 
normocin (InvivoGen) (DPBSgn). Colon tissue was cut into lengthwise strips (approximately 3 
mm x 5 mm). Tissue was incubated in 10 mM DTT for 15 minutes at room temperature, 
changing to fresh DTT every 5 minutes. Tissue was rinsed in DPBSgn, rinsed once with 8 mM 
EDTA, and then incubated/rotated in 8mM EDTA at 4°C for 75 minutes. EDTA was removed 
and tissue was washed three times with DPBSgn. Tissue was then “snap-shook” 10x to manually 
separate colon crypts. The crypt-containing supernatant was immediately added to 1.5 mLs of 
cold FBS in a BSA-coated 50 mL tube and the shake step was repeated twice more. Crypts were 
spun at 40 x g for 2 minutes at 4°C. The pellet was washed in DPBSgn and spun again at 40 x g 
for 2 minutes at 4°C. The pellet was resuspended in a solution of 66% matrigel (Corning), 33% 
KGMG-media (KGMG Bullet Kit, Lonza), and 10 µM of the ROCK inhibitor, Y27632, 
(Miltenyi) at a concentration of 2 crypts/µL, accounting for 250 µL per well in a 6-well plate. 
Four diagonal strips of 60 µL of the culture was added to each well in a pre-warmed cell culture 
plate using a cut tip. After 30 minutes, media containing 10 µM Y27632 was added. Media was 
changed daily for three days. On the fourth day, cultures were treated with either vehicle or 100 
µM of the PHD inhibitor, FG-4592 (Cayman Chemicals), overnight and then lysed directly in 
Trizol for qPCR analysis.    
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Data analysis 
Error bars represent the standard deviation (25). P values were calculated by independent 
t test, paired t-test, one-way ANOVA, Dunnett t test, and two-way ANOVA. 






















HIF-2α is essential in inflammation-induced colon tumorigenesis 
 One of the most commonly utilized models to study intestinal tumorigenesis is the 
ApcMin/+ model. These mice harbor a germline truncation mutation to the Apc gene and 
spontaneously develop intestinal adenomas (26). However, this model does not completely 
recapitulate human colon tumorigenesis as the vast majority of these tumors develop in the small 
intestine with few colon tumors observed. Moreover, few of these tumors progress beyond 
adenoma and rarely become invasive. Inflammation is an essential component of the colon tumor 
microenvironment and previous studies have shown that acute colonic inflammation induced by 
dextran sulfate sodium (DSS) can increase the incidence of colon tumorigenesis in the ApcMin/+ 
mouse (27). To directly determine the functional role for HIF-2α expression in inflammation-
induced colon tumorigenesis, mice with intestine-epithelial specific disruption of HIF-2α (Hif-
2αΔIE) by villin-cre mediated recombination were crossed to ApcMin/+ mice (Hif-2αΔIE/ApcMin/+) 
and compared to littermate controls with intact HIF-2a expression (Hif-2αF/F/ApcMin/+). The Hif-
2αΔIE/ApcMin/+ mice had significantly reduced colon tumor number and reduced tumor burden 
(Fig. 2.1A-D). Furthermore, tumors from Hif-2αΔIE/ApcMin/+ mice had significantly increased 
apoptosis as measured by terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling 
(TUNEL) staining (Fig. 2.1E and F). These results show that colon-epithelial HIF-2α is 
important in inflammation-driven colon tumorigenesis.  
 Epithelial expression of HIF-2α can promote inflammatory responses (10) and can 
modulate the immune environment in tumors. Colon tumors from Hif-2αF/F/ApcMin/+ had a 
significant increase in the pan-myeloid cell marker CD11b compared to adjacent normal tissue. 
However, tumors from Hif-2αΔIE/ApcMin/+ had a significant reduction in tumor CD11b compared 
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to those from Hif-2αF/F/ApcMin/+, suggesting tumor epithelial expression of HIF-2α regulates 
myeloid cell influx into tumors. To determine the precise myeloid cell type absent, qPCR 
analysis was conducted for monocyte, macrophage, and neutrophil markers. Significantly less 
expression of neutrophil markers Ly6g and myeloperoxidase (Mpo) were observed in Hif-
2αΔIE/ApcMin/+ colon tumors compared to Hif-2αF/F/ApcMin/+ mice, whereas no changes in 
expression of the monocyte marker CD68 or macrophage markers Emr1, iNos, or Arg1 were 
observed (Fig. 2.1G). Moreover, the calcium binding protein, S100a8, which is abundantly 
expressed by neutrophils is significantly reduced in both normal and tumor tissue from Hif-
2αΔIE/ApcMin/+ (Fig. 2.1H) (28). These data suggest epithelial cell expression of HIF-2α is 
essential for the recruitment of neutrophils in colon tumors. 
 To assess if HIF-2α is sufficient to drive colon tumorigenesis, mice with overexpression 
of O2-stable HIF-2α downstream of a loxP-STOP-loxP (LSL) cassette knocked-in to the Rosa26 
allele (10) were crossed to ApcMin/+ mice to generate Hif-2αLSL/ApcMin/+ mice. These mice develop 
significantly more colon tumors compared to age-matched HIF-2α wild-type controls (Hif-
2α+/+/ApcMin/+) at 3 months (Fig. 2.2A and B). Moreover, these tumors have significantly higher 
proportion of proliferating cells as shown by incorporation of Bromodeoxyuridine (BrdU) (Fig. 
2.2C and D). Concurrent with increased tumorigenesis, tumors from Hif-2αLSL/ApcMin/+ mice 
have higher presence of neutrophils compared to Hif-2α+/+/ApcMin/+ mice by Ly6G 
immunofluorescence (Fig. 2.2E). 
 
HIF-2α regulates intratumoral neutrophils in colitis-associated colon cancer 
 In order to appropriately model the role for HIF-2α in the inflammatory progression of 
colon cancer, we used the AOM/DSS model of CAC in mice with intestine-epithelial specific 
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deletion of HIF-2α (Hif-2αΔIE) (29). Hif-2αΔIE and littermate control mice (Hif-2αF/F) were 
injected i.p. with AOM (10mg/kg) on day 0 and treated with DSS (1.5%wt/vol) in their drinking 
water beginning day five for five-days and changed back to regular drinking water for two-weeks 
for three cycles. Consistent with the inflammation-induced ApcMin/+ model, Hif-2αΔIE mice have 
significantly reduced colon tumor number compared to littermate controls, suggesting HIF-2α 
expression is essential for inflammation-induced colon tumorigenesis (Fig. 2.3A). To analyze 
neutrophil infiltration in tumors, flow cytometry was performed on individual colon tumors. 
Colon tumors from Hif-2αΔIE had a significant reduction of CD11b+Ly6G+ neutrophils from the 
colon tumor microenvironment compared to Hif-2αF/F colon tumors (Fig. 2.3B and C). No 
changes in tumor macrophages (CD11b+/F4/80+) were observed (Fig. 2.3D and E). These data 
suggest epithelial HIF-2α modulates the colon tumor microenvironment through regulating 
infiltration of tumor-associated neutrophils.  
 
HIF-1α does not impact colon tumorigenesis or neutrophil recruitment 
Our studies suggest that HIF-2α is a major regulator of colitis associated colon 
tumorigenesis through recruitment of pro-tumorigenic neutrophils. To address overlap in 
function of HIF-2α and HIF-1α in colon tumorigenesis, we assessed the role of HIF-1α using 
mice with intestine epithelial disruption of HIF-1α (Hif-1αΔIE). In the AOM/DSS model of colitis 
associated colon cancer, no difference in tumorigenesis was observed in Hif-1αΔIE compared to 
WT controls (Hif-1αF/F) (Fig. 2.4A and B). Concurrently, no changes in expression of neutrophil 
markers (Ly6g and Cd11b) were observed in Hif-1αF/F colon tumor tissue relative to Hif-1αΔIE 
colon tumor tissue (Fig. 2.4C).  
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Colon-epithelial HIF-2α regulates neutrophil chemotaxis 
 To determine if epithelial HIF-2α can regulate neutrophil chemotaxis, we used a 
transwell assay. Neutrophils were isolated from bone marrow and were shown to be highly pure 
(over 80%) (Fig. 2.5A). Isolated colon explants used were from mice with epithelial deletion of 
Von-Hippel Lindau (VhlΔIE). Previous work has shown that these mice promote intestinal 
epithelial stabilization of HIF-2α in normoxic conditions (18). A dramatic increase in neutrophil 
migration through the transwell towards colon explants from VhlΔIE compared to WT (VhlF/F) 
colon tissue explants was observed (Fig. 2.5B and C). To more directly assess the effects of HIF-
2α, media was conditioned with colon tissue from HIF-2α-overexpressing mice (Hif-2αLSL) and 
this led to a significant increase in neutrophil transwell chemotaxis compared to colon tissues 
explant from wild-type littermate mice (Hif-2α+/+) (Fig. 2.5B and C). These data demonstrate 
that HIF-2a is important in neutrophil recruitment in vitro. Flow cytometery analysis of normal 
colon tissue from mice overexpressing HIF-2α in the intestinal epithelium (Hif-2αLSL) showed a 
significant increase in intra-colonic neutrophils compared to wild-type littermate mice (Fig. 2.5D 
and E). Together, these data demonstrate an essential and sufficient role of epithelial HIF-2α in 
neutrophil recruitment in the colon.  
 
CXCL1 is highly induced by intestinal epithelial HIF-2a. 
Neutrophils are recruited to solid tumors through tumor secretion of cytokines and 
chemokines (30). To determine the precise mechanism for how epithelial HIF-2α recruits 
neutrophils into intestine, RNA-seq analysis were performed in colon tissues from Hif-2αLSL and 
WT (Hif-2α+/+) mice. Pathway analysis identified neutrophil attractive chemokines such as 
Cxcl1, Cxcl2 and Cxcl5 and neutrophil markers such as S100a8 were highly increased in the 
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colon tissues from Hif-2αLSL mice (Fig. 2.6A and B). Expression of several members of the CXC 
family of chemokines was examined by qPCR from colon tissue of HIF-1α overexpressing mice 
(Hif-1α LSL), and Hif-2α LSL mice, and littermate controls. Only Cxcl1 expression was robustly 
increased (p<0.001) in colon tissue in Hif-2α LSL mice compared to WT and Hif-1α LSL mice (Fig. 
2.6C). These data suggest that activated epithelial HIF-2α in colon tumors may recruit 
neutrophils through secretion of cytokines and chemokines. 
 
HIF-2α is an essential regulator of CXCL1 expression in colon tumors 
 Oncomine data analysis indicated that CXCL1 was highly increased in human 
colon tumors compared to normal colon tissues (Fig. 2.7A and B). We further confirmed by 
qPCR that CXCL1 was significantly increased in a set of colon tumor tissues compared to their 
adjacent normal colon tissues (Fig. 2.7C). CXCL1 expression is induced in colon tumors but the 
major regulators of CXCL1 expression in colon tumors are currently unknown. Consistent with 
patient tumor analysis, CXCL1 expression was highly induced in AOM/DSS-induced colon 
tumors in Hif-2αF/F mice compared to normal adjacent tissue. This increase was significantly 
attenuated from tumors isolated from Hif-2αΔIE mice (Fig. 2.7D and E). No difference in Cxcl1 
expression was observed in tumors from Hif-1αF/F or Hif-1αΔIE mice (Fig. 2.7F). 
The tumor microenvironment is a complex milieu of tumor epithelial cells, immune cells, 
and stromal cells. Previous genetic analysis has suggested that in tumor xenograft models, 
greater than 99% of the Cxcl1 transcripts are expressed directly by the tumor epithelial cells 
relative to tumor stromal cells (31). To evaluate if epithelial hypoxia signaling directly regulates 
Cxcl1 expression, we generated colon enteroids from mice with colon epithelial specific deletion 
of Apc, activation of the oncogene Kras, and loss of Tp53 tumor suppressor, which are 
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commonly observed mutations in human colon tumors (Fig. 2.7F). Colon enteroids are an ideal 
model to mechanistically study CRC because they maintain cell polarization and tight junctions 
in three-dimensions and the cultures can be generated from primary colon epithelial tissue 
harboring mutations that are most commonly selected for in human colon tumors (32). To 
activate hypoxia signaling, these enteroids were treated with the potent PHD inhibitor FG-4592, 
which stabilizes HIF in normoxic conditions (33). Compared to untreated enteroids, activation of 
hypoxia significantly induced Cxcl1 expression, demonstrating that epithelial hypoxia signaling 
is sufficient to activate Cxcl1 expression (Fig. 2.7G). Taken together, our data suggest that 
epithelial HIF-2α is a master regulator of CXCL1 expression in colon tumors.  
 
HIF-2α-regulates CXCL1 promoter through HRE- and MAZ-dependent mechanisms 
 HIFs activate target gene transcription through binding to hypoxia response elements 
(HREs), which are defined as 5’-RCGTG-3’, in promoter and enhancer regions. Analysis of the 
CXCL1 proximal promoter identified six canonical HREs clustered at distal and proximal sites 
(Fig. 2.8A). The proximal promoter region of Cxcl1 was cloned into the pGL3-luciferase reporter 
construct. Using co-transfection in HCT116 cells, overexpression of an oxygen-stable HIF-2α 
was shown to directly activate the Cxcl1 promoter similar to HIF-2α activation of the well-
characterized HREs of the enolase promoter (P2.1) (Fig. 2.8B). To evaluate the dependence of 
these HREs in HIF-2α-mediated CXCL1 induction, a series of deletion constructs to disrupt the 
HREs were generated. HIF-2α activation of Cxcl1 promoter was attenuated when the distal 
HREs were deleted and completely ameliorated when both the distal and proximal HREs were 
removed. These data demonstrate that the HREs are essential for HIF-2α-mediated CXCL1 
promoter induction (Fig. 2.8C). 
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It has been suggested that target gene specificity for HIF-1α and HIF-2α is mediated by 
interactions with other transcription cofactors (34). Previously, our work has shown that HIF-2α 
inflammatory target gene activation is dependent upon interaction with an essential cofactor, 
Myc-associated zinc finger (35) (10, 36). MAZ is a cys2his2-type zinc finger transcription factor 
that is highly upregulated in several human cancers and regulates tumor growth (37). To 
determine if MAZ is essential for HIF-2α-dependent CXCL1 promoter induction, we used two 
targeting shRNAs to generate stable knockdowns of MAZ expression in HCT116 cells (MAZ 
sh1 and MAZ sh2) (Fig. 2.8D). Compared to cells stably expressing scrambled shRNA (Ctrl 
cells), MAZ sh1 & MAZ sh2 significantly attenuated CXCL1-promoter activation in response to 
HIF-2α (Fig. 2.8E).  
 
CXCR2 inhibition reduces HIF-2α-driven colon tumorigenesis 
 CXCL1 induces neutrophil recruitment through binding its cognate receptor, CXCR2, 
expressed on the cell surface of neutrophils. To determine if CXCL1 signaling through CXCR2 
is the major mechanism by which epithelial HIF-2α mediates neutrophil recruitment, we use a 
well-characterized CXCR2 blocking peptide mimetic, CXCR2 pepducin. CXCR2 is a G-protein 
coupled receptor and pepducins block CXCR2 signaling and decrease neutrophil influx into sites 
of inflammation and tumors (38, 39). Bone marrow derived neutrophils were isolated and treated 
with the CXCR2 pepducin (Pep) or control pepducin (Veh). Blocking CXCR2 completely 
attenuated HIF-2a-induced neutrophil migration (Fig. 2.9A and B). 
We next assessed the functional role for neutrophil recruitment in HIF-2α-driven colon 
tumorigenesis. To investigate this axis, we used the AOM/DSS model of CAC in VhlΔIE mice. 
Previous work has shown these mice have a higher propensity to develop colon tumors in a HIF-
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2α-dependent manner (9). Unlike the Hif-2αLSL mice, VhlΔIE mice can survive 3 cycles of DSS. 
To confirm that epithelial deletion of Vhl increases Cxcl1 expression, we isolated purified colon 
epithelial cells (CECs) and intraepithelial lymphocytes (40) in VhlΔIE and VhlF/F mice. Cxcl1 
expression is significantly increased in CECs of VhlΔIE mice compared to VhlF/F mice but not in 
intraepithelial lymphocytes (IELs) (Fig. 2.9C). Moreover, CXCL1 expression is induced in 
VhlΔIE mice in a HIF-2α-dependent manner using mice with double disruption of VHL and HIF-
2α (VhlΔIE/ Hif-2αΔIE)  (Fig. 2.9D). To address the role of CXCR2-mediated neutrophil 
recruitment to colon tumors, VhlΔIE were randomized to treatment with Ctrl-pepducin (Veh) or 
CXCR2-pepducin (Pep) once daily for days 65-100 by subcutaneous injection following the third 
cycle of DSS, (Fig. 2.9E). Compared to littermate control VhlF/F mice, VhlΔIE mice treated with 
Ctrl-pepducin developed significantly more colon tumors and had higher tumor burden and 
increased neutrophil influx (Fig. 2.9F-H). The VhlΔIE mice treated with CXCR2-pepducin 
significantly reduced HIF-2α-driven colon tumorigenesis and neutrophil infiltration. In addition, 
tumors from VhlΔIE mice had a significant increase in tumor cell proliferation measured by Ki67 
immunofluorescence staining, which was attenuated in VhlΔIE mice treated with CXCR2-
pepducin (Fig. 2.9I and J). Taken together, our studies suggest that HIF-2α-mediated neutrophil 
recruitment through CXCL1-CXCR2 axis is essential for its role in colon tumorigenesis.  
 
Discussion 
Inflammation and hypoxia are intimately linked and hypoxia has been previously shown 
to regulate the inflammatory microenvironment of many tumor types. Hypoxia increases ovarian 
cancer tumor growth through secretion of CCL28, which facilitates recruitment of immune 
suppressive T regulatory (Treg) cells to promote tumor growth (41). In pancreatic ductal 
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adenocarcinoma, HIF-1α is a tumor suppressor through blockade of pro-tumorigenic B cell 
recruitment to tumors (42). Interestingly, our data shows that epithelial expression of HIF-2α can 
modulate the inflammatory milieu of colon tumors through regulating the recruitment of 
intratumoral neutrophils. Hypoxic regulation of cytokines and chemokine secretion from tumor 
cells can modulate neutrophil recruitment to promote hepatocellular carcinoma (43). 
Additionally, neutrophils tend to be localized to hypoxic zones within uterine tumors (25). 
Mechanistically, we have discovered a novel HIF-2α target gene, CXCL1. CXCL1 is a member 
of the C-X-C family of chemokines and is a potent neutrophil chemoattractant to sites of 
inflammation or tumors through binding its cognate receptor, CXCR2 (44). Consistent with our 
work showing that epithelial CXCL1 is induced by HIF-2a, previous studies using xenograft 
models demonstrate the vast majority (>99%) of Cxcl1 transcripts in colon tumors are derived 
from tumor epithelial cells (31). Our studies clearly demonstrate that the epithelial HIF-2a can 
regulate Cxcl1 induction in colon tumors.  
The functional role for neutrophils in the progression of tumors is not clear, as both anti-
tumorigenic (N1) and pro-tumorigenic (N2) neutrophils have been described (13). Neutrophils 
expressing the hepatocyte growth factor (HGF) receptor, c-MET, have been shown to be largely 
anti-tumorigenic in colon tumors (35). However, large-scale meta-analysis studies have shown 
that neutrophils correlate highly with adverse outcomes across more than 25-different tumor 
types (45). Neutrophils are critical mediators of metastasis in murine models of breast cancer 
(40). It has also been suggested that neutrophils are essential in the inflammatory progression of 
colon tumors as depletion of neutrophils with anti-Ly6G antibody significantly reduced colon 
tumors (46). Moreover, a high neutrophil to lymphocyte ratio portends poor prognosis for colon 
cancer patients (47). In our study, we show that HIF-2α-driven colon tumorigenesis is dependent 
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upon neutrophil influx into colon tumors through the neutrophil CXCL1 receptor, CXCR2. A 
critical role for CXCR2 in the initiation and progression of colon cancer and pancreatic ductal 
adenocarcinoma has been described (48, 49). Inhibition of neutrophil influx via CXCR2 
decreased HIF-2α-driven colon tumorigenesis, progression, and proliferation. These studies 
demonstrate mechanistically how hypoxic inflammatory responses can modulate the colon tumor 
immune microenvironment to promote tumor growth. More work is needed to determine the 
precise mechanisms by which neutrophils promote colon tumorigenesis.  
The studies reported herein suggest that that epithelial HIF-2α, but not HIF-1α, 
selectively modulates neutrophil recruitment into tumors without affecting other myeloid cell 
populations. Neutrophils are critical to setup an oxygen gradient in the intestine (50). These 
oxygen gradients promote tissue repair in a HIF-1α-dependent manner. HIF-1α is highly active 
in intestinal inflammation and genetic deletion of intestinal epithelial HIF-1α exacerbates colitis 
(51). HIF-1α is an essential regulator of expression of intestinal barrier protective genes such as 
intestinal trefoil factor (Itf), CD73, and multidrug resistance gene 1 (Mdr-1) (51, 52). The 
bidirectional signaling of hypoxia and neutrophil may be a feed forward mechanism mediated by 
HIF-2α critical to establish an oxygen gradient during acute inflammation for HIF-1α-dependent 
injury repair (50).  However, our data suggest in chronic inflammation this mechanism 
exacerbates tumorigenesis. 
Previously, we have shown that activation of HIF-2α can promote colon tumor cell 
growth in a cell-autonomous manner. Epithelial expression of HIF-2α is a potent activator of 
inflammatory responses and increases the progression of intestinal inflammation (10). 
Additionally, HIF-2α is a transcriptional regulator of pro-inflammatory cyclooxygenase 2 
(COX2) and microsomal prostaglandin e synthase (mPGES) to increase tumor inflammation and 
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treatment of HIF-2α-overexpressing mice with the anti-inflammatory, nimesulide, can reduce 
colon tumorigenesis (24). Interestingly, HIF-1α activation has no effect on colon tumorigenesis 
(53). Similarly, we find that HIF-1α has no effect on the expression of Cxcl1. Previous studies 
have highlighted the dichotomous role for HIF-1α and HIF-2α in several cancer models. For 
example, in renal cell carcinoma, HIF-2α is essential for tumor cell growth whereas HIF-1α 
decreases cell growth (54). In pancreatic cancer, genetic mouse models demonstrate that HIF-2α 
is essential for tumorigenesis whereas HIF-1α decreases tumorigenesis through repression of 
infiltrating pro-tumorigenic B cells (55, 56). However, in lung cancer it has been shown that 
HIF-2α exerts a tumor suppressive effect (57). These studies demonstrate the careful need to 
evaluate the tumor specific roles for HIF-1α and HIF-2α for therapeutic targeting. HIF-2α-
specific inhibitors have been developed which target a novel ligand-binding pocket that is 
located within the PAS-B domain of HIF-2α but not in HIF-1α (58). These novel tools may 
provide an exciting therapeutic avenue to decrease tumor cell proliferation as well as decrease 
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pGL3-mCxcl1-luc1685 F 5'-ACGTGGTACCAGCTAATCTTAGGA 
pGL3-mCxcl1-luc345 F 5'-ACGTGGTACCCACTGTAGTACACC 
pGL3-mCxcl1-luc285 F 5'-ACGTGGTACCTGACCCACCTCG 
pGL3-mCxcl1-R 5'-ACGTCTCGAGGTGGAGCTCTAG 
qPCR Primers 
mCxcl1 F 5'-TCTCCGTTACTTGGGGACAC 
mCxcl1 R 5'-CCACACTCAAGAATGGTCGC 
hCxcl1 F 5'-AACAGCCACCAGTGAGCTTC 
hCxcl1 R 5'-GAAAGCTTGCCTCAATCCTG 
CD11b F 5'-ATGGACGCTGATGGCAATACC 
CD11b R 5'-TCCCCATTCACGTCTCCCA 
CD11c F 5'-CTGGATAGCCTTTCTTCTGCTG 
CD11c R 5'-GCACACTGTGTCCGAACTCA 
Emr1 F 5'-CCCCAGTGTCCTTACAGAGTG 
Emr1 R 5'-GTGCCCAGAGTGGATGTCT 
CD68 F 5'-CTTCCCACAGGCAGCACAG 
CD68 R 5'-AATGATGAGAGGCAGCAAGAGG 
iNOS F 5'-ACCCTAAGAGTCACCAAAATGGC 
iNOS R 5'-TTGATCCTCACATACTGTGGACG 
Ly6G F 5'-TGGACTCTCACAGAAGCAAAG 
Ly6G R 5'-GCAGAGGTCTTCCTTCCAACA 
Mpo F 5'-AGTTGTGCTGAGCTGTATGGA 
Mpo R 5'-CGGCTGCTTGAAGTAAAACAGG 
S100a8 F 5'-CCAATTCTCTGAACAAGTTTTCG 






Figure 2.1. HIF-2a is essential for inflammation-induced colon tumorigenesis. 
(A) Hif-2α+/+/ApcMin/+ (n=5) and Hif-2αΔIE/ApcMin/+ (n=7) were treated for 5-days with DSS and 
analyzed 28-days following final day of DSS administration. (B) Tumor number, (C) tumor 
burden and (D) Gross image in the colon from Hif-2α+/+/ApcMin/+ and Hif-2αΔIE/ApcMin/+ mice 25 
days following DSS administration.  (E) Representative images of H&E analysis and TUNEL 
staining, (F) quantification of TUNEL positive cells in tumor tissue from Hif-2α+/+/ApcMin/+ and 
Hif-2αΔIE/ApcMin/+ mice. (G) qPCR expression analysis of myeloid cell markers and (H) S100a8 
in tumors and/or adjacent normal tissue from Hif-2α+/+/ApcMin/+ and Hif-2αΔIE/ApcMin/+.  * 
p<0.05, ** p<0.01 and *** p<0.001 compared to Hif-2α+/+/ApcMin/+mice, ## p<0.01, ### 
p<0.001 compared to normal tissue. Statistical analysis was performed by student’s t-test or two-










Figure 2.2. HIF-2a increases inflammation-induced colon tumorigenesis. 
(A) Tumor number from colon tissue of Hif-2α+/+/ApcMin/+ (n=8) and Hif-2αLSL/ApcMin/+ mice 
(n=9). (B) Representative images of H&E analysis. (C) Representative images of BRDU 
incorporation in tumors from Hif-2α+/+/ApcMin/+ and Hif-2αLSL/ApcMin/+ mice. (D) Quanitficaiton 
from (C). * p<0.05. (E) Representative images of Ly6G immunofluorescence in tumors from 












Figure 2.3. Disruption of intestinal epithelial HIF-2a decreases colon tumors and 
intratumoral neutrophils in a colitis-associated colon cancer model (CAC).  
(A) Tumor number from colons of Hif-2αF/F (n=11) and Hif-2αΔIE (n=14) following AOM/DSS 
induced CAC. (B) Flow cytometry analysis of CD11b/Ly6G double positive cells or (D) 
CD11b/F4/80 double positive cells gated from CD45+ cells in tumors from Hif-2αF/F and Hif-
2αΔIE mice. Tumors were collected from individual mice. (C and E) Quantification from flow 
cytometry data in tumors ** p<0.01 and *** p<0.001 compared to Hif-2α+/+ mice. Statistical 






















Figure 2.4. HIF-1α does not impact colon tumorigenesis or neutrophil recruitment.  (A) 
Tumor number from colons of Hif-1αF/F (n=8) and Hif-1αΔIE (n=6) following AOM/DSS induced 
CAC. (B) Representative images of H&E staining from Hif-1αF/F and Hif-1αΔIE tumor tissue. (C) 
qPCR of Cd11b and Ly6g expression in tumor tissue from (A). Statistical analysis was 





















Figure 2.5. Intestinal HIF-2a activation promotes recruitment of neutrophils to the colon. 
(A) Flow cytometric analysis of CD11b/Ly6G staining of bone marrow isolated neutrophils. (B) 
Representative images of neutrophil or (C) quantification of cell numbers migrated into the 
bottom well of a transwell towards VhlF/F, VhlΔIE, Hif-2α+/+, Hif-2αLSL colon tissue explants. (D) 
Flow cytometry analysis and (E) quantification of CD11b/Ly6G double positive cells gated from 
CD45+ cells in colon tissue from Hif-2αLSL mice compared to Hif-2α+/+ mice. * p<0.05 and *** 


















                             
 
Figure 2.6. Activation of intestinal epithelial HIF-2a increases CXCL1 expression. Volcano 
plot of RNA-Seq analysis in colon tissues from Hif-2α+/+ (n=6) and Hif-2αLSL mice (n=6). (B) 
Heatmap of genes related to cytokine activity enriched by PANTHER gene ontology analysis 
from Hif-2α+/+ and Hif-2αLSL colon tissues. (C) qPCR analysis of CXC-family of chemokines in 
colon tissue from WT,  Hif-1αLSL, and Hif-2αLSL mice. * p<0.05 and ** p<0.001 compared to 
normal colon tissues. Statistical analysis was performed by one-way ANOVA followed by 
Dunnett's multiple comparisons test. 
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Figure 2.7. Epithelial HIF-2a is essential for CXCL1 expression in colon tumors  
Oncomine database analysis of CXCL1, CXCL2 and neutrophil markers in several independent 
microarrays analysis from colon cancer and normal tissue. CXCL1 gene expression in (B) The 
Cancer Genome Atlas (TCGA) dataset and (C) a set of 8 pairs of colon tumor and adjacent 
normal tissue collected at University of Michigan (Umich). (D) qPCR analysis of Cxcl1 mRNA 
or (E) ELISA analysis of CXCL1 protein in CAC tumor tissue and adjacent normal tissue from 
Hif-2αF/F and Hif-2αΔIE  mice. (F) qPCR analysis of Cxcl1 expression in tumors from Hif-1αF/F 
and Hif-1αΔIE mice. (G) Representative image of colon enteroids following deletion of Apc and 
TP53 and activation of Kras. (H) qPCR of Cxcl1 expression in colon enteroids treated with FG-
4592 or vehicle control (Ctrl). * p<0.05. *p<0.05, ** p<0.01 and *** p<0.001 compared to WT, 
Hif-2αF/F or Ctrl. ## p<0.01, ### p<0.001 compared to normal tissue. Expression was normalized 
to β-Actin. Statistical analysis was performed by Student’s t-test, paired t-test or two-way 
ANOVA followed by Sidak's multiple comparisons test. 
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Figure 2.8. HIF-2a and MAZ are essential for CXCL1 activation.  
Analysis of the Cxcl1 proximal promoter shows there are six HREs present (I-VI) in proximal 
and distal areas. (B) Cxcl1 or the enolase (P2.1) promoter luciferase activity assays in HCT116 
cells expressing HIF-2α. (C) Cxcl1 promoter luciferase activity assays with deletion constructs in 
HCT116 cells expressing HIF-2α. (D) qPCR and western blot analysis of MAZ knockdown 
efficiency in HCT116 cells expressing MAZ targeting shRNAs (MAZ sh1 & MAZ sh2). (E) 
CXCL1-promoter luciferase activity assay in HCT116 cells expressing MAZ targeting shRNAs. 
*p<0.05, ** p<0.01 and *** p<0.001 compared to EV or Ctrl. Statistical analysis was performed 




Figure 2.9. HIF-2a-mediated neutrophil recruitment is essential for colon tumorigenesis. 
(A) Representative images of neutrophils and (B) quantification from Ctrl pepducin (Veh) or 
CXCR2 pepducin (PEP) treated migrated into the bottom well of a transwell towards Hif-2α+/+ 
and Hif-2αLSL colon tissue explants. (C) qPCR analysis of Cxcl1 expression in colon epithelial 
cells (CEC) compared to intraepithelial lymphocytes (IEL) of VhlF/F and VhlΔIE mice. (D) ELISA 
analysis of CXCL1 protein in colon tissue of VhlF/F (n=6), VhlΔIE (n=3), VhlΔIE/Hif-2αΔIE (n=4) 
mice. (E) Schematic diagram for AOM/DSS-induced CAC and CXCR2 pepducin treatment 
protocol. (F) Tumor counting (G) tumor burden analysis, (H) representative images of H&E 
staining and Ly6G staining and (I) Ki67 staining and (J) quantification of Ki67 staining in colon 
tissue from VhlF/F (n=4), VhlΔIE + Veh (n=4), and VhlΔIE + PEP (n=3) groups. ** p<0.01 
compared to VhlF/F.  ## p<0.01 compared to VhlΔIE + CXCR2 pepducin. Statistical analysis was 











Neutrophils are among the most prevalent immune cells in the microenvironment of 
colon tumors. Neutrophils are largely believed to favor colon tumor growth and are predictive 
biomarkers for colon cancer patients. Clinical trials targeting neutrophil trafficking in cancer are 
initiated. However, very little is known about neutrophil function in the early steps of colon 
tumorigenesis. To clearly understand the role of neutrophils in colon cancer we utilized mice 
with constitutive genetic depletion of neutrophils. In an inflammation-induced and sporadic 
colon tumor models, depletion of neutrophils increased progression and invasion of colon 
tumors. Mechanistically, neutrophil depletion correlated with increased tumor-associated 
bacteria, high intratumoral B-cells, increased proliferation, heightened DNA damage, and 
heightened inflammatory response through IL-17 and NF-"B. Antibiotic treatment or B-cell 
depletion in neutrophil deficient animals dramatically reversed tumor progression. Our findings 






It has become widely appreciated that in addition to genetic hits such as APC loss, KRAS 
activation, and TP53 loss, the tumor immune response plays a critical role in the neoplastic 
progression of colon cancer (1). Chronic inflammation of the colon, in the form of inflammatory 
bowel disease (IBD), is a significant risk factor for the development of colon cancer. The colon 
tumor immune microenvironment consists of cells in the innate and adaptive response with 
variable roles in tumor growth (1). Anti-tumor immune cells, such as T-cell and natural killer 
cells dampen tumorigenesis and tumor progression and pro-tumorigenic immune cells such as T-
regulatory cell and tumor associated macrophages foster tumor growth and immune evasion (2). 
As tumors progress, mechanisms such as decreased tumor O2 tension alter immune cell 
differentiation and effector functions to tip the balance in favor of the pro-tumor immune 
response and enhance tumor growth and progression (2). Better understanding of the tumor 
immune response may provide novel therapeutic avenues for treatment of disease. 
Polymorphonuclear neutrophils (PMNs) are myeloid cells of the innate immune system 
known for their role in the acute host response to infection. PMN effector functions consist of 
bacterial phagocytosis, generation and release of cytotoxic granule proteins, and production of 
superoxide radicals (3). Evidence has emerged that PMNs are among the most prevalent immune 
cells type in several human cancers, including colon cancer, pancreatic cancer, and lung cancer 
(4). The functional role for PMNs in the progression of cancer has largely been suggested to be 
pro-tumorigenic through suppression of antitumor immunity and direct activation of tumor cell 
growth (5, 6). Recent meta-analysis demonstrates PMNs have the highest correlation with 
adverse outcomes across all cancers (7). Despite these observations, the primary contribution of 
PMNs to the initiation of colon tumorigenesis is not clear. Therefore, a more thorough 
	 69 
investigation of PMNs in cancer is necessary to identify their potential for therapeutic targeting 
in colon cancer.  
The majority of studies have relied upon antibody mediated PMN depletion and PMN 
trafficking receptor inhibitors which may have off-target effects and may not completely 
eradicate intra-tumoral PMNs in colon cancer. In the current study, a murine model of genetic 
PMN depletion was assessed in mouse models of colitis and colon cancer. Genetic depletion of 
PMNs robustly enhanced tumor progression and invasion in a colitis-associated tumor model as 
well as a sporadic colon tumor model. Interestingly, genetic PMN depletion promoted a dramatic 
expansion of tumor-associated bacteria that was critical for the increased tumor progression. This 
also led to accumulation of intra-tumoral B-cells which played an important role in increased 
tumor growth and progression. Therapeutic targeting of granulocytic myeloid cells and PMNs is 
currently being evaluated for clinical utility in several cancer types (4). Our data delineates an 
important role for neutrophils in blunting colon tumor progression and invasion and provides 
caution against anti-PMN therapy in colon cancer, particularly in the context of preceding 




For all experiments, male and female mice aged 6 to 8-weeks were used. All mice are 
C57BL/6 background. LysMCre;Mcl1fl/fl mice were previously described (8). All animals used are 
C57BL/6 background. To delineate the role of neutrophils in colon cancer, the AOM/DSS model 
was utilized. For AOM/DSS experiments, animals were injected I.P. with 10mg/kg 
azoxythmethane then cycled on and off DSS in their drinking water for seven days for three 
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cycles interspersed with two weeks of regular drinking water beginning five-days following 
AOM injection. For acute DSS experiments, animals were treated with 2.5% DSS in drinking 
water for seven days then changed back to regular drinking water for two days. Cdx2-
CreERT2;Apcfl/fl mice have been previously described (9). Mrp8-Cre  expressing mice were 
previously described and crossed to Mcl-1fl/fl mice (10). Bone marrow transplantation was 
performed by isolation of single cell suspension of bone marrow cells from femur and tibia of 6- 
to 8-week old mice LysMCre;Mcl1fl/fl, Mrp8Cre;Mcl1fl/f, and LysMCre;Mcl1wt/wt mice. 1x10^6 bone 
marrow cells were injected into the tail vein of recipient mice lethally irradiated with two split 
doses of 6gy radiation four-hours apart. Mice were supplemented with Neomycin (1g/ml) in their 
drinking water for two-weeks. Four-weeks post transplantation, recipient mice were injected I.P. 
with tamoxifen (100mg/kg) in corn oil and sacrificed 14-days after administration. For 
antibiotics treatment, AOM/DSS was induced in LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl mice 
with 1.5% DSS. 14-days after administration of AOM, mice were placed on antibiotics drinking 
water (neomycin 1mg/ml, ampicillin 1mg/ml, and streptomycin 0.5mg/ml). Every other day, 
mice were orally gavaged with antibiotics solution (neomycin 2.5mg/ml, ampicillin 2.5mg/ml, 
streptomycin 1.25mg/ml, and metronidazole 1.25mg/ml) and sacrificed 72-days after AOM 
administration. For B-cell inhibition experiments, colon tumorigenesis was initiated in 
LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl mice using AOM and 1.5% DSS. One-week following 
the third cycle of DSS, LysMCre;Mcl1fl/fl mice were randomized into Ctrl and anti-B220 treatment 
groups (BioXcell). Mice were treated every fourth day with 400ug I.P. anti-B220 diluted in 
sterile 1x PBS pH 7.0.  
   
Flow cytometry 
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Fresh normal and colon tumor tissue were finely minced followed by incubation with 
Collagenase Type II (Sigma-Aldrich) (1mg/ml) 1-hour in cold HBSS. Digested tissues were then 
passed through a 40um cell strainer. Peripheral blood was prepared by lysing one drop of tail 
blood for twenty minutes with RBC lysis buffer. White blood cells were then pelleted and passed 
through a 40um cell strainer. Single-cell suspensions were stained with eFluor780- anti-CD45 
(eBioscience), PE-anti-Ly6G (BD), APC-anti-Cd11b (eBioscience), FITC-anti-B220 
(eBioscience) and eFluor450 anti-F4/80 (eBioscience). Flow cytometry was performed using an 
LSRFortessa (BD). Flow cytometry data was analyzed using FlowJo software (BD Biosciences).  
 
Histology and immunofluorescence 
Colon tissue was excised, cut longitudinally, swiss-rolled, and fixed in 10% formalin 
overnight. Tissues were then embedded in paraffin and cut in 5µm sections and stained with 
hematoxylin and eosin and scored by a blinded gastroenterology pathologist. Tumor invasion 
scoring was done as previously described (11). Immunofluorescence was performed following 
antigen retrieval of 5um paraffin slides. Antibodies for immunofluorescence were as follows: 
Ki67 (1:100, Vector Labs), p-H2AX (1:200, Cell Signaling Technologies), cCasp3 (1:800, Cell 
Signaling Technologies) and Alexa Fluor® 488 goat anti-rabbit IgG (1:500, Molecular Probes 
Inc). B220 staining was performed following antigen retrieval of 5um paraffin slides using anti-
B220 FITC antibody (eBioscience). Bacteria labeling was performed with Cy3 labeled EUB338 
probe (5’-Cy3 GCTGCCTCCCGTAGGAGT). Briefly, paraffin tissue sections were 
deparaffinized in xylenes (2x for 5 minutes) followed by 100% ethanol (2x for 5 minutes) then 
rinsed in D.I. water. Slides were incubated with 100ul of 5ng/ul EUB338 for two hours at 46OC 
in hybridization buffer (35% formamide, 20mM Tris-HCl pH7.2, 0.9M Nacl, 0.01% SDS) then 
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washed for 40 minutes at 48OC and mounted with ProLongTM Gold reagent with Dapi 
(Invitrogen). cCasp3 and p-H2AX were quantified using ImageJ software as number of positive 
cells per high powered field (HPF). EUB338 was quantified as percent of EUB338 positive area 
per Dapi positive area.  
 
RNA isolation, qPCR analysis  
RNA was isolated using TRIzol reagent (Ambion). RNA was reverse transcribed to 
cDNA using MMLV reverse transcriptase (Fisher Scientific). qPCR analysis was performed 
using Radiant Green qPCR mix (Alkali Scientific Inc.). 
 
Protein isolation and Western blotting 
Tissues were lysed in radioimmunoprecipitation assay buffer (RIPA) (50 mmol/L Tris-
HCl pH 7.5, 150 mmol/L NaCl, 2 mmol/L EDTA, 1% NP-40, 0.1% SDS). Proteins were 
separated and using SDS-PAGE and transferred to nitrocellulose membrane. Antibodies used are 
as follows: phosphor-P65 (1:1000, Cell Signaling Technologies), total-P65 (1:1000 Cell 
Signaling Technologies), phospho-STAT3 (1:1000, Cell Signaling Technologies), total-STAT3 
(1:1000 Cell Signaling Technologies), GAPDH (1:1000, Santa Cruz Biotechnology), PCNA 
(1:1000, Cells Signaling Technologies). 
 
IgA ELISA 
Fecal IgA was measured using Mouse IgA ELISA Quantitation Kit according to 
manufacturer’s protocol (Bethyl Laboratories, Inc). 
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High throughput RNA sequencing (RNA-seq) and RNA-Seq data analysis 
TruSeq RNA library prep kit v2 (Illumina) was used to prepare RNA sequencing 
libraries. Libraries were sequenced using single-end 50-cycle reads on a Illumina HiSeq 2500 
sequencer. The Flux high-performance computer cluster at the University of Michigan was used 
for computational analysis. RNA-seq read quality was assessed utilizing FastQC. Reads were 
aligned to a splice junction aware build of the mouse genome (mm10) using STAR(12) with the 
options “outFilterMultimapNmax 10” and “sjdbScore 2”. Differential expression testing between 
WT and Mcl-1+/-, Mcl-1-/- colon samples was conducted with CuffDiff v 2.1.1 with the parameter 
settings “-compatible-hits-norm,” and “–frag-bias-correct”. UCSC mm10.fa was used and the 
GENCODE mouse M12 primary assembly annotation GTF as the reference genome and 
reference transcriptome, respectively. Genes were considered differentially expressed at a false-
discovery rate-adjusted (FDR) P value of <0.05. 
 
16S rRNA gene sequencing and bacterial community analysis 
 Feces were collected at 65 and 75-days after AOM/DSS induced colon tumorigenesis in 
LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl mice. At day 75, tumors were collected and snap frozen. 
Bacterial sequencing was performed at the Microbial Systems Molecular Biology Lab. The 
Dual-indexing sequencing strategy was used to amplify the V4 region of the 16s rRNA gene 
from each sample. PCR was performed under the following conditions 95oC, 2min; [950C, 20 
secs; 550C, 15 secs] – 30 cycles; 720C, 10 min; 40C using Accuprime High Fidelity Taq 
(ThermoFisher). Samples were normalized using the SequalPrep Normalization plate kit 
(ThermoFisher). Sequencing was done on the Illmina MiSeq platform, using a MiSeq Regent Kit 
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V2 500 cycles, according to the manufacturer’s instructions (13). Bacterial Community analysis 
was done base on Mothur wiki.  
 
Statistical analysis 
P-values were calculated by students t-test or one-way ANOVA. Error bars represent 
standard error of the mean.  
 
Results 
Neutrophil deficiency enhances the acute inflammatory response in colitis  
PMN infiltration in IBD is a marker of disease severity and progression (14). In acute 
DSS-induced colitis in mice, neutrophils robustly infiltrated inflamed mucosal tissues as early as 
4-days after initiation of colitis, were maintained through active inflammation at 7-days, and 
were quickly lost during resolution (Fig. 1A & B). Macrophage influx is milder and less robust 
(Fig. S1A & B). To dissect the role for PMNs in the inflammatory progression of colitis, we 
utilized mice with a genetic neutrophil deficiency. Mcl-1, an anti-apoptotic member of the Bcl-2 
family, is a PMN-specific survival molecule when disrupted in myeloid cells using LysM-cre 
(LysMCre;Mcl1fl/fl) (Fig. 1C) (8). Mice with myeloid deficiency of Mcl-1 had greater than 50% 
reduction of circulating PMNs in heterozygous floxed animals (LysMCre;Mcl1fl/wt) and greater 
than 90% reduction in PMNs in homozygous floxed animals (LysMCre;Mcl1fl/fl) (Fig. 1D & E). 
This was accompanied by no significant change in the number of circulating monocytes as 
previously reported (Fig. S2A) (15). Furthermore, no changes in basal histological colon 
architecture and cell proliferation were observed (Fig. S2B& C).  
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To evaluate the function of PMN depletion of the acute response in the DSS-injury 
model, LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl mice were treated with 2.5% DSS in their 
drinking water for 7-days then changed back to regular drinking water for 2-days. Compared to 
LysMCre;Mcl1wt/wt mice, LysMCre;Mcl1fl/fl mice failed to recover body weight by 9-days and had 
significant colon length shortening (Fig. 1F & G). Histologic analysis shows significant 
destruction of colonic architecture in LysMCre;Mcl1fl/fl colon tissue compared to 
LysMCre;Mcl1wt/wt and higher histopathologic inflammation score than LysMCre;Mcl1wt/wt (Fig. 1H 
& I). Interestingly, PMN-deficiency did not change expression of Tnfa and Il22, but correlated 
with increased expression of Il17 and Il6 (Fig. 1J).  
 
Neutrophils inhibit colitis-associated colon tumorigenesis. 
Next, the functional role for genetic PMN depletion in inflammation-induced cancer of 
the colon was assessed. PMNs are among the most prevalent immune cell type in the colon 
tumor microenvironment in the AOM/DSS model (Fig. S3A & B). The function for PMNs in the 
progression of inflammation-induced colon cancer has largely been suggested to be pro-
tumorigenic (16). However, genetic PMN ablation early in colon tumorigenesis has not been 
assessed. To address this, LysMCre;Mcl1wt/wt, LysMCre;Mcl1fl/wt, and LysMCre;Mcl1fl/fl mice were 
I.P. injected with AOM (10mg/kg) and cycled on and off 2% DSS in their drinking water and 
sacrificed at day 87 after AOM administration (Fig. 2A). Weight loss is a surrogate for morbidity 
in AOM/DSS-induced colitis-associated colon tumorigenesis. By the end of the third cycle of 
DSS, LysMCre;Mcl1fl/fl mice failed to recover body weight by day 87 (Fig. 2B). Compared to 
LysMCre;Mcl1wt/wt animals, LysMCre;Mcl1fl/fl mice developed significantly larger tumors (Fig. 2C 
& D). No change in the total tumor number was observed between LysMCre;Mcl1wt/wt, 
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LysMCre;Mcl1fl/wt, and LysMCre;Mcl1fl/fl mice (Fig. 2E). However, the tumor burden and average 
tumor size were significantly increased in LysMCre;Mcl1fl/fl mice (Fig. 2F & G). To confirm 
depletion of neutrophils was maintained in colon tumors, flow cytometric analysis of primary 
tumor tissue was performed. Whereas 30-40% of the white blood cells (WBCs) present in tumors 
from LysMCre;Mcl1wt/wt mice were double positive for CD11b and Ly6g, less than 10% of the 
WBCs were double positive in LysMCre;Mcl1fl/wt mice, and virtually no double positive cells 
were detected in the LysMCre;Mcl1fl/fl mice (Fig. 2H and I). No change in the percentage of 
tumor-associated macrophages was observed (Fig. S4A & B). These data suggest that PMNs 
play a critical role in inhibiting colitis-associated colon tumorigenesis by restricting tumor size 
and growth. 
 
Neutrophil depletion increases colon tumor invasion and proliferation. 
 In the AOM/DSS model, highly invasive disease is rare and in many cases requires 
additional genetic hits (11). Further histologic characterization of colon tumors showed that no 
tumors in LysMCre;Mcl1wt/wt mice developed into invasive adenocarcinomas (Fig. 3A). Strikingly, 
25% of tumors from LysMCre;Mcl1fl/wt mice were invasive adenocarcinomas and this was 
potentiated in the LysMCre;Mcl1fl/fl mice as greater than 60% of colon tumors in LysMCre;Mcl1fl/fl 
mice were invasive (Fig. 3B). 16% of tumors from LysMCre;Mcl1fl/fl had invaded through 
muscularis propria and many tumors could be detected in perirectal fat (Fig. 3C & D). In 
addition to increased tumor invasion, PMN depletion dramatically increased colon tumor 
proliferation as measured by Ki67 incorporation and proliferating cell nuclear antigen (PCNA) 
expression (Fig. 3E & F). No significant difference in tumor cell apoptosis was observed (Fig. 
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S5A & B). These data delineate an important function for intra-tumoral PMNs in restricting 
tumor invasion and proliferation. 
 
Neutrophil depletion enhances tumor progression in genetic colon cancer models. 
The data thus far shows that PMNs restrict tumor progression in inflammation-driven 
colon tumors. However, the vast majority of colon tumors are not preceded by chronic 
inflammation and develop due to mutations in the Adenomatous polyposis coli (APC) gene (17). 
In mice, truncation of a single Apc allele is sufficient to cause spontaneous intestinal 
tumorigenesis, albeit the vast majority of these tumors are localized to the small intestine (18). 
Mice with a colon-specific disruption of Apc using the colon-specific homeobox 2 (Cdx2) Cre 
(Cdx2-CreERT2; Apcfl/fl) develop colon tumors after administration of tamoxifen (9). To 
understand the role of PMN depletion in sporadic tumorigenesis, Cdx2-CreERT2; Apcfl/fl mice 
were transplanted with bone marrow from either LysMCre;Mcl1wt/wt or PMN-deficient 
LysMCre;Mcl1fl/fl mice (Fig. 4A). Chimeras transplanted with LysMCre;Mcl1fl/fl bone marrow had 
depleted circulating PMNs (Fig. 4B and C). Cdx2-CreERT2;Apcfl/fl mice were administered a 
single injection of tamoxifen (100mg/kg, I.P.) and were sacrificed and analyzed for early 
neoplastic changes 14-days after tamoxifen injection. In LysMCre;Mcl1wt/wt chimeras, only low-
grade adenomas were observed. In LysMCre;Mcl1fl/fl chimeras, 3 out of 7 mice developed 
submucosal invasive adenocarcinoma (AdenoCa-T1) (Fig. 4D & E). This suggests that PMNs 
restrict early tumor progression in colon cancer independent of acute exacerbations of colitis in 
the AOM/DSS model.  
LysM-Cre is expressed in multiple myeloid cell types including monocytes, mature 
macrophages, and granulocytes (19). Therefore, off-target effects cannot be excluded. We next 
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assessed the dependence of PMN-specific Mcl-1-deletion for the enhanced tumor progression. 
To specifically delete Mcl-1 in PMNs, Mcl-1 floxed animals were crossed to the PMN-specific 
Mrp8-Cre transgenic mice (10). Cdx2-CreERT2;Apcfl/fl animal chimeras transplanted with 
Mrp8Cre;Mcl1-/- bone marrow chimeras had significant reduction of circulating PMNs (Fig. 4 F-
H). Mrp8Cre;Mcl1-/- mice had no significant difference in circulating monocytic cells (Fig. S6A 
& B). Strikingly, at fourteen days after tamoxifen administration, Mrp8Cre;Mcl1-/- bone marrow 
recapitulated the increased invasiveness observed in LysM;Mcl-1-/- mice with areas of invasion 
into and through the muscularis propria (Fig. 4I & J). These data indicate that PMN depletion 
early in sporadic colon tumorigenesis dramatically increases progression and invasion.  
 
Neutrophils restrict colon tumor-associated bacteria expansion 
To identify mechanisms by which PMN-depletion enhanced colon tumor progression, 
RNA-seq analysis was performed on tumor tissue from LysMCre;Mcl1wt/wt, LysMCre;Mcl1fl/wt, and 
LysMCre;Mcl1fl/fl mice. Several genes with known roles in anti-microbial defense were 
significantly reduced (Cfd, Lyz2, Defa27, Mcpt1) (Fig. 5A). Additionally, several B-cell 
associated genes (Ighd, Ighg1, Fcmr) were highly upregulated (Fig. 5A). Neutrophils are well 
described for their anti-microbial and phagocytic functions. Neutrophil deficient LysMCre;Mcl1fl/fl 
mice have previously been shown to have higher attachment and decreased eradication of the 
pathogenic bacteria Citrobacter rodentium in the colon (15). To assess for tumor-associated 
bacteria, we performed fluorescence in situ hybridization (FISH) using a universal bacterial 
probe (EUB338). Relative to AOM/DSS tumors from LysMCre;Mcl1wt/wt mice, PMN-deficient 
tumors have increase in tumor-associated bacteria (Fig. 5B & C). Bacteria can induce intra-
tumoral genetic instability through promoting DNA double-stranded breaks (20). PMN-deficient 
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tumors had significantly more phosphorylated histone p-H2AX (Fig. 5D & E). IL-17 was 
identified as a highly-expressed cytokine in RNA-seq analysis in Mcl-1-/- colon tumors (Fig. 5A). 
Colon tumor-associated microbes drive tumor progression through activation of IL-17 expression 
(21). Moreover, epithelial attachment of pathogenic microbes can directly induce an IL-17 
response (22). Our data has shown in acute DSS-colitis, LysMCre;Mcl1fl/fl mice had an increased 
colon IL-17 response. LysMCre;Mcl1fl/fl colon tumors also had significantly increased Il17 
expression compared to LysMCre;Mcl1wt/wt (Fig. S7A). High activation of bacterial-activated 
inflammatory pathways such as NF-#B and STAT3 were also observed (Fig. S7B). 
We next assessed alterations in microbiota by bacterial sequencing of fecal and primary 
tumor samples from LysMCre;Mcl1wt/wt and  LysMCre;Mcl1fl/fl mice after AOM/DSS induced colon 
tumorigenesis.. No significant changes in tumor-associated and fecal bacterial diversity were 
detected (Fig. S7C). However, several bacteria species were significantly altered in tumors and 
feces of LysMCre;Mcl1fl/fl mice (Fig. 5F). Interestingly, Akkermansia, a mucinolytic bacteria 
previously shown to be associated with human colon tumors was significantly increased in 
tumors from LysMCre;Mcl1fl/fl mice (23)REF. Furthermore, Proteobacteria was significantly 
decreased in tumors from LysMCre;Mcl1fl/fl mice, which has previously been suggested to be 
decreased in human colon tumors (24). Collectively, these data suggest that PMNs play an 
important role in restricting bacterial dysbiosis in colon tumors.  
 
Colon microbiota are essential for increased tumor growth in PMN-deficient mice 
 PMN-deficiency greatly increased intra-tumoral bacteria and bacteria-dependent 
responses (Fig. 5). The colon microbiota is strongly associated with initiation and progression of 
colon tumors (25). Several bacterial species have been proposed to have a direct causal role in 
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colon cancer. Fusobacterium nucleatum can directly potentiate colon cancer growth and 
enhances ß-Catenin signaling (26). To evaluate the contribution of bacteria to tumor growth, 
LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl were induced by AOM/DSS and beginning on day 14 
after AOM treatment LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl mice were randomized into Ctrl and 
antibiotics treatment groups (Fig. 6A). LysMCre;Mcl1fl/fl bone marrow chimeras had significantly 
reduced PMNs one-day prior to AOM administration (Fig. 6B). Whereas, LysMCre;Mcl1fl/fl mice 
developed dramatically larger colon tumors than LysMCre;Mcl1wt/wt mice, antibiotic treatment 
decreased tumor size and decreased tumor burden with no change in total tumor number in 
LysMCre;Mcl1fl/fl mice (Fig. 6C-F). Antibiotics treatment reduced PMN-deficient tumor-
associated genetic instability (Fig. 6G). Furthermore, antibiotics dramatically reduced tumor 
invasion in LysMCre;Mcl1fl/fl mice (Fig. 6H). Collectively, these data define an important 
contribution of colon microbiota to enhanced tumor growth and progression observed in PMN-
deficient animals.  
 
Neutrophils restrict expansion of colon tumor-associated B cells 
 Antibiotics treatment partially but not completely reversed the PMN-deficient increase in 
colon tumor progression, suggesting other mechanisms promote growth and invasion. In addition 
to anti-microbial genes, RNA-seq data showed many genes associated with B-cells were higher 
in LysMCre;Mcl1fl/fl colon tumors. Immunofluorescence and flow cytometric analysis of tumors 
showed robust infiltration of B-cells into primary tumors from PMN-depleted mice compared to 
LysMCre;Mcl1wt/wt mice (Fig. S8A & B). No changes in circulating B-cells or fecal IgA were 
observed in untreated LysMCre;Mcl1fl/fl mice (Fig. S8C-E). In addition to heightened B-cell 
infiltration into the primary tumor, B-cells were also directly associated with highly invasive 
	 81 
areas in colitis-associated and sporadic tumors from LysMCre;Mcl1fl/fl mice (Fig. 7A and Fig 
S8F). The close association of B-cells with invasive tumors suggested a potential role for these 
cells in the neoplastic progression of PMN-depleted colon tumors. To define the functional role 
of B-cells in LysMCre;Mcl1fl/fl mice, we decided to target B-cells using anti-B220 antibody-
mediated B-cell inhibition (27). To evaluate the ability of anti-B220 therapy to decrease B-cells 
from colonic tissue during inflammation, mice were treated with 2.5% DSS and were 
randomized to Ctrl or anti-B220 antibody (400ug I.P.) treatment in acute DSS-colitis (Fig. S9A). 
Circulating B-cells and intracolonic B-cells were significantly decreased after three doses anti-
B220 antibody (Fig. S9B & C). This treatment did not have a significant effect on the acute 
inflammatory response in colitis (Fig. S9D-F).  
 To assess B-cells in the progression of PMN-deficient tumors, colon tumorigenesis was 
induced in LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl mice using AOM/DSS. Immediately following 
the third cycle of DSS, LysMCre;Mcl1fl/fl animals were randomized into Ctrl and anti-B220 treated 
groups and treated beginning every fourth day from Day 50 through Day 75 (Fig. 7B). 75-days 
post induction of colon tumorigenesis, anti-B220 treatment reduced colon B-cells (Fig. 7C). No 
change in tumor number was detected between any groups (Fig. S10A). However, tumor burden 
and tumor size were dramatically increased in LysMCre;Mcl1fl/fl mice relative to LysMCre;Mcl1wt/wt 
control animals (Fig. 7D & E). B-cell inhibition from LysMCre;Mcl1fl/fl mice improved the 
observed increase in tumor burden and tumor size (Fig. 7D & E). Furthermore, B-cell depletion 
led to a reduction in the percentage of invasive adenocarcinomas and increased percentage of 




The functional role for neutrophils in neoplastic progression has been controversial, 
however, the vast majority of work suggests a pro-tumorigenic role for PMNs in tumorigenesis. 
PMN and granulocytic-cell targeted therapeutics have been proposed for the treatment of several 
tumor types (4). Peptide-mimetics targeting the G-protein coupled receptor CXCR2 which 
mediates PMN and myeloid-derived suppressor cells (MDSCs) infiltration into tumors is 
efficacious in dampening colon tumorigenesis in both colitis-associated as well as sporadic colon 
tumor models (28). Peptide Fc-fusion proteins (peptibodies) targeting the S100 family of protein 
expressed on MDSCs and PMNs have also shown to dampen tumor growth in preclinical models 
(29). Clinical trials in breast cancer targeting PMNs have been initiated (30). However, PMN 
infiltration into human colon tumors was associated with both positive and adverse clinical 
outcomes (31, 32). Experiments using mouse models further raise questions about the function of 
PMNs in the initiation and progression of colon tumors as conflicting data on the role of PMNs 
have been shown. Our work clearly demonstrates depletion of neutrophils early in colon 
tumorigenesis profoundly enhances tumor growth, proliferation, and invasion. 
Discrepancies between neutrophil function in our study relative to others could perhaps 
be explained by differences in models. For example, anti-Ly6G antibody depletion of PMNs is 
commonly used in tumor studies (33). Interestingly, flow cytometric analysis suggests Cd11b-
/Ly6G+ exist, which could perhaps suggest non-PMN targets of this treatment may affect the 
robust reduction in colitis-associated tumors observed in this model (34). Although CXCR2 is 
not completely PMN selective, deletion of the chemokine receptor CXCR2 results in reduced 
Cd11b+/Ly6g+ infiltration into colon tumors and significant reduction in colon tumorigenesis 
(34). Strategies to inhibit CXCR2 may be effective in inhibiting a subset of neutrophils. 
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Intratumoral PMN heterogeneity has been proposed to partly explain the differential effects of 
PMN depletion on tumorigenesis (35-38). Moreover, a landmark study showed that PMN 
plasticity can be driven towards protumor “N2” PMNs or antitumor “N1” PMNs in a TGF-ß-
dependent manner. Approaches to target all tumor-associated neutrophils as described in the 
present work potentiate disease progression. Moreover, this is the first study to our knowledge to 
use a complete neutrophil deficient mouse in the study of colon cancer. Other models of genetic 
neutrophil depletion have been used in the study of other cancers. The Csf3r knockout mouse fail 
to develop PMNs and enhance tumor growth in a murine uterine tumor model (39).  
The colon microbiota and microbial dysbiosis drive colon tumorigenesis (25). This idea 
is highlighted with studies from germfree mouse models which show decreased colon 
tumorigenesis in the absence of microbiota (40). Furthermore, E. coli species were directly 
linked to tumor invasion (41). Key factors regulating the expansion, diversity, and evolution of 
tumor-associated microbiota in colon cancer are not well understood. Our studies have 
delineated a novel mechanism for intra-tumoral PMNs restricting microbiota-dependent tumor 
progression. Deletion of PMNs profoundly increased tumor-associated bacteria and many known 
microbiota-dependent responses, including genetic instability, IL-17 response, and NF-#B 
activation, all of which with known critical roles in neoplastic progression. Additionally, PMN 
depletion impacted the microbiota associated with colitis-associated colon tumors in mice. 
Importantly, antibiotics treatment reduced PMN-deficient tumor progression and invasion. 
Future studies aimed at determining the precise bacteria associated with PMN-deficient tumors 
are currently in progress.  
The precise function for PMNs in the progression of IBD is not well known. Chronic 
granulomatous disease (CGD), a primary deficiency in the NADPH oxidase complex resulting in 
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inability of neutrophils to generate reactive oxygen species to kill pathogens, can predispose 
patients to development of IBD-like disease that resembles Crohn’s disease (42). This suggests a 
role for PMN anti-microbial functions in restricting spontaneous colitis. Recently, it has been 
suggested that in addition to the pathogen killing function, decreased PMN-mediated O2-
consumption through decreased ROS production in Chronic Granulomatous Disease reduces 
hypoxia-inducible transcription factor-1a (HIF-1a) activity, an essential regulator of colon 
epithelial barrier integrity (43). In addition to the ROS-mediated mucosal protection, PMN-
secreted IL-22 has also been shown to have an important role in activating expression of 
epithelial-derived antimicrobial peptides, although no changes in Il22 mRNA abundance was 
observed in our studies (44). Several studies suggesting a prominent role for PMNs in promoting 
inflammatory responses have been reported (14). The data in our studies suggest that neutrophil 
depletion in LysMCre;Mcl1fl/fl mice recapitulates aspects of the enhanced inflammatory response 
in colitis seen in Chronic Granulomatous Disease patients. Future experiments more specifically 
addressing mechanisms of increased colitis in LysMCre;Mcl1fl/fl mice and the contribution to 
microbiota are currently under investigation 
One of the more surprising finings of our study is the enhanced tumor invasion in 
response to PMN depletion. This response was not due solely to enhanced inflammation in 
colitis, as genetic colon tumor models also displayed increased local invasiveness following 
PMN depletion. PMNs have been generally characterized as critical drivers of tumor cell 
invasion and metastasis. PMNs are purported to increase tumor invasion be secreting enzymes 
such as matrix metalloproteinase 9 (MMP9) (45). In hepatocellular carcinoma, PMNs were 
shown to directly initiate an epithelial-mesenchymal transition in tumor cells (46). PMNs were 
recently shown to suppress Natural Killer (NK) cell-mediated breast cancer cell killing and 
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promote tumor cell extravasation (47). Also in breast cancer, PMNs induced by IL-17 producing 
T-cells were found to increase tumor metastasis through repression of CD8 T-cells (48). 
However, PMNs have also been shown to limit metastatic seeding of tumors in the lung through 
generation of H2O2 (49). Our findings demonstrate in colon cancer that depleting neutrophils 
early in tumors leads to cell invasion through all layers of the colon mucosae. Thus, targeting of 
PMNs therapeutically in human colon cancer may exacerbate disease.  
PMN-deficient tumors were highly infiltrated with B220+ B-cells. Analogous to PMNs, 
B-cell function in tumors is not well understood and could perhaps have both pro- and anti-tumor 
functions (50-53). Our data indicate that B-cells expand in PMN-deficient tumors and are highly 
associated with invasive areas. Moreover, inhibition of B-cells decreased tumor size and 
decreased tumor invasion in PMN-deficient mice. Previous reports suggested that B-cells in 
colon lymphoid follicles were an early site of tumor cell invasion in rat and mouse models of 
colon cancer (54). It has also been suggested that human colon cancers are highly associated with 
B-cells and lymphoid follicles (55). B-cells associated with invasive areas and promoted tumor 
growth and invasion in our model. These data suggest further study into the regulation, 
recruitment, and functional role of B-cells in colon cancer are warranted.  
It is possible that the effects observed in our studies are due to complete absence of 
PMNs prior to induction of tumorigenesis. The role for PMNs in the initiation of colon cancer 
are controversial. Our data suggest a mechanism by which PMNs restrict tumor-associated 
bacteria and B-cells, which are essential for colon tumor growth and progression (Fig. 7G). 
Clinical studies suggest PMNs are a positive prognostic indicator in early stage colon cancer 
(31). Studies in mice have proposed that PMNs in early stage tumors retain antitumor functions 
but a phenotypic switch to a more immunosuppressive state occurs throughout tumor progression 
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(56). It is possible that similar mechanisms exist in colon cancer whereby the earliest tumor 
infiltrating PMNs serve to inhibit expansion of colon microbiota and B-cells to limit 
tumorigenesis and progression. Whereas, PMNs in established tumors evolve a more pro-
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Figure 3.1. Neutrophil depletion exacerbates acute colitis. (A) Representative flow cytometry 
dot plots (D=days of DSS treatment) and (B) quantification of flow cytometric analysis of 
peripheral blood neutrophils using Ly6g and Cd11b in WT and Mcl-1-/- mice treated with 2.5% 
DSS. (C) Schematic of Mcl-1 deletion in myeloid cells using LysozymeM (LysM)-cre 
(LysMCre;Mcl1fl/fl) (D) Representative dot plots and (E) quantification of flow cytometric analysis 
of peripheral blood neutrophils using Ly6g and Cd11b staining gated on total lymphocytes in 
LysMCre;Mcl1wt/wt, LysMCre;Mcl1fl/wt, and LysMCre;Mcl1fl/fl mice. ***p<0.001 and ****p<0.0001 
relative to LysMCre;Mcl1wt/wt, #p<0.05 compared to LysMCre;Mcl1fl/wt. (F) Body weight, (G) colon 
length, (H) representative hematoxylin & eosin staining, and (I) histopathologic inflammation 
score of LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl mice treated with 2.5% DSS. ***p<0.001, 
*p<0.05. (J) qPCR analysis of indicated genes *p<0.05 relative to LysMCre;Mcl1wt/wt. Statistical 





Figure 3.2. Neutrophils restrict colitis-associated colon tumor progression. (A) Schematic of 
AOM/DSS-induced colon tumorigenesis. Mice were I.P. injected with AOM on Day 0 then 
cycled on and off 2% DSS in their drinking water for three cycles with two-weeks between then 
sacked at day 87. (B) Body weight, (C) representative images of whole mount specimens, (D) 
hematoxylin and eosin (H&E) staining of indicated mice after AOM/DSS. Body weight shown 
as a percentage of Day 0. of AOM/DSS treated colon tissue from LysMCre;Mcl1wt/wt, 
LysMCre;Mcl1fl/wt, and LysMCre;Mcl1fl/fl mice. (E) Tumor number, (F) tumor burden, and (G) 
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average tumor size of colon tumors. *p<0.05, **p<0.01, ***p<0.001 relative to 
LysMCre;Mcl1wt/wt, ##p<0.01 relative to LysMCre;Mcl1fl/wt. (H) Flow cytometric analysis and (I) 
quantification of Cd11b and Ly6g staining from primary colon tumors. ***p<0.001 relative to 
LysMCre;Mcl1wt/wt. ##p<0.01 relative to LysMCre;Mcl1fl/wt. Statistical analysis was performed with 





















Figure 3.3. Neutrophils limit tumor progression and invasion. (A) Representative H&E of 
staining of adenoma from LysMCre;Mcl1wt/wt mice and (B) invasive adenocarcinoma from 
LysMCre;Mcl1fl/fl mice at 10x and 20x magnification. (C) Representative image of H&E of 
invasive AdenoCa-T2, AdenoCa-T3, and colon tumor cells in perirectal fat in LysMCre;Mcl1fl/fl 
mice. (D) Quantification of percentage of low-grade adenomas (Adeno-lg), high-grade adenomas 
(Adeno-Hg), submucosal invasive adenocarcinomas (AdenoCa-T1), muscularis invasive 
adenocarcinoms (AdenoCa-T2), and invasive through muscularis (AdenoCa-T3) in 
LysMCre;Mcl1wt/wt, LysMCre;Mcl1fl/wt, and LysMCre;Mcl1fl/fl  mice. (E) Representative image of 
Ki67 staining of colon tumors in LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl  mice. (F) Western blot 
analysis of proliferating cell nuclear antigen (PCNA) of colon tumors from LysMCre;Mcl1wt/wt, 
LysMCre;Mcl1fl/wt, and LysMCre;Mcl1fl/fl  mice.  
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Figure 3.4. Neutrophils restrict progression of sporadic colon tumorigenesis. (A) Schematic 
of bone marrow transplantation from LysMCre;Mcl1wt/wt (n=6) and LysMCre;Mcl1fl/fl  (n=7) mouse 
donors to Cdx2-CreERT2;Apcfl/fl mice. (B) Flow cytometric do plot analysis and (C) 
quantification of Cd11b and Ly6g staining of peripheral blood. **p<0.01 relative to WT. (D) 
Representative H&E images of low grade adenomas (AdenoLg) in LysMCre;Mcl1wt/wt and 
LysMCre;Mcl1fl/fl  and invasive adenocarcinoma T1 (AdenoCaT1) in LysMCre;Mcl1fl/fl  mice. (E) 
Quantification of colon tumor stage in indicated mice. (F) Schematic of bone marrow 
transplantation from Mrp8Cre;Mcl1wt/wt  (n=3) and Mrp8Cre;Mcl1fl/fl  (n=3) mouse donors to Cdx2-
CreERT2;Apcfl/fl mice. (G) Flow cytometric do plot analysis and (H) quantification of Cd11b and 
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Ly6g staining of peripheral blood. **p<0.01 relative to Mrp8Cre;Mcl1wt/wt  . (I) Representative 
H&E images of low grade adenomas (AdenoLg) in Mrp8Cre;Mcl1wt/wt  and Mrp8Cre;Mcl1fl/fl  and 
invasive adenocarcinoma T2 (AdenoCa-T2) and adenocarcinoma T3 (AdenCa-T3). (J) 




























Figure 3.5. Neutrophils limit tumor-associated bacteria. (A) Heat map of RNA-seq analysis 
of colon tumors from LysMCre;Mcl1wt/wt, LysMCre;Mcl1fl/wt, and LysMCre;Mcl1fl/fl mice. (B) 
Representative images fluorescence in situ hybridization (FISH) using universal bacteria 
EUB338 probe labeled with Cy3 colon tumors from LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl 
mice. (C) Quantification of EUB338 positive area per high powered field (HPF). *p<0.05. (D) 
Representative images and (E) quantification of immunofluorescence staining of p-H2AX in 
LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl colon tumors. *p<0.05. (F) Heat map of significantly 
altered tumor-associated (Day 75) and fecal bacteria (Day 65 & Day 75) in LysMCre;Mcl1fl/fl mice 




Figure 3.6. Microbiota promotes tumor progression in PMN-deficient mice. (A) Schematic 
of AOM/DSS-induced colon tumorigenesis.  (B) Quantification of circulating Cd11b+/Ly6g+ 
cells in indicated mice. ***p<0.001 (C) Representative grow whole mount specimens, (D) tumor 
number, (E) tumor burden and (F) tumor size of colon tumors in LysMCre;Mcl1wt/wt and 
LysMCre;Mcl1fl/fl treated with antibiotics or control. ****p<0.0001, ***p<0.001. (G) 
Representative H&E analysis and (H) quantification of colon tumor progression from 
LysMCre;Mcl1wt/wt, LysMCre;Mcl1fl/fl, and LysMCre;Mcl1fl/fl mice treated with antibiotics. (I) 
Representative p-H2AX immunofluorescence staining. Statistical analysis was performed with 




Figure 3.7. B-cells are important in PMN-deficient colitis-associated colon tumor model. 
(A) Representative H&E and B220 staining from LysMCre;Mcl1fl/fl tumor tissue of invasive 
adenocarcinoma.  (B) Schematic of AOM/DSS-induced colon tumorigenesis. Anti-B220 
treatment was initiated at day 54 with 400ug/mouse treatement every fourth day. (C) 
Representative flow cytometric analysis of B220 staining in colon tissue from Ctrl and anti-B220 
treated Mcl-1-/- mice. (D) Tumor burden, (E) tumor size, and (F) quantification of colon cancer 
stage in indicated mice. with anti-B220 antibody or control. *p<0.05 relative to 
LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl plus antibiotics. ** ##p<0.001 relative to LysMCre;Mcl1fl/fl 
+ anti-B220, and **p<0.01 relative to all groups >3.0mm. Statistical analysis performed by 
either student’s t-test or one-way ANOVA followed by Tukey’s multiple comparison’s test. (G) 
Neutrophils restrict colon tumor progression and invasion by restricting outgrowth of tumor-
associated microbiota and limiting infiltration of B-cells. (H) We propose a model in which 
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PMNs in the earliest stage colon tumors inhibit tumorigenesis through repression of tumor-
associated bacteria as well as other potential mechanisms such as stimulation of T-cells. In later 
stage colon tumors, PMNs acquire pro-tumorigenic function and inhibit anti-tumor immunity, 












































Figure S3.1. Macrophage infiltration in DSS colitis. (A) Representative flow cytometry dot 




Figure S3.2. Characterization of LysMCre;Mcl1fl/fl mice. (A) Representative flow cytometry 
dot plots of F4/80+/Cd11b+ cells in peripheral blood. (B) Representative H&E staining and (C) 
Ki67 immunofluorescence from LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl mouse colon tissue.  
	 102 
 
Figure S3.3. Neutrophils are highly infiltrated in AOM/DSS colon tumors. (A) 
Representative flow cytometry dot plots and (B) quantification of Ly6g+/Cd11b+ cells in 
AOM/DSS colon tumors from WT mice. ****p<0.001. Statistical analysis performed by 





Figure S3.4. Tumor infiltration of macrophages is unaltered in Mcl-1-/- mice. (A) 
Representative flow cytometry dot plots and (B) quantification of F4/80+/Cd11b+ cells in colon 
tumors from LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl mice. Statistical analysis performed by 












Figure S3.5. PMN depletion does not alter colon tumor apoptosis. (A) Representative 
immunofluorescence cleaved caspase 3 (cCasp3) and dapi from LysMCre;Mcl1wt/wt and 
LysMCre;Mcl1fl/fl mice colon tumors. (B) Quantification of cCasp3 positive cells per high 






Figure S3.6. Monocytes are unchanged in Mrp8-Cre/Mcl-1-/- mice. (A) Representative flow 
cytometry dot plots and (B) quantification of Ly6c+/Cd11b+ cells as a percentage of total 
myeloid cells from Mrp8Cre;Mcl1wt/wt and Mrp8Cre;Mcl1fl/fl mice. Statistical analysis performed 
by student’s t test. 
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Figure S3.7. PMN depletion increases microbiota-dependent inflammatory responses. (A) 
Quantitative PCR analysis of Il17 expression in LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl colon 
tumors. **p<0.01. (B) Western blot analysis of colon tumors from WT, Mcl-1+/-, and Mcl-1-/- 
mice.  Statistical analysis was performed with student’s t-test. (C) Principal component analysis 
of bacterial composition in LysMCre;Mcl1wt/wt and LysMCre;Mcl1fl/fl tumor and fecal samples. 
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Figure S3.8. Increased B-cells in PMN-deficient colon tumors. (A) Flow cytometric analysis 
and (B) representative images of B220 staining of colon tumor tissue from LysMCre;Mcl1wt/wt and 
LysMCre;Mcl1fl/fl mice. (C) Flow cytometric analysis of B220 staining and (D) quantification of 
peripheral blood B-cells. (E) IgA ELISA analysis from feces of LysMCre;Mcl1wt/wt and 
LysMCre;Mcl1fl/fl mice. (F) Representative immunofluorescence of B220 staining from WT tumor 
tissue and invasive adenocarcinoma tissue from LysMCre;Mcl1fl/fl mouse. Statistical analysis 
performed by student’s t test. 
	 106 
 
Figure S3.9. B-cell depletion does not exacerbate DSS colitis. (A) Schematic of 2.5% DSS 
treatment and anti-B220 injections (400ug/mouse I.P.) on days 1, 3, and 5. (B) Representative 
flow cytometric analysis of B220 staining in peripheral blood and colon tissue and (C) 
quantification B-cells of Ctrl and anti-B220 treated animals. (D) Representative H&E histologic 
analysis (E) colon length and (F) total inflammation score of treated mice. Statistical analysis 










Figure S10. B-cell depletion reduces PMN-deficient tumor progression. (A) Tumor number 
and (B) representative histologic analysis indicated tumor stage from Ctrl and anti-B220 treated 
LysMCre;Mcl1fl/fl mice. Statistical analysis was performed by one-way ANOVA followed by 


























Myc-Associated Zinc Finger Protein Regulates the Pro-Inflammatory Response in Colitis 
and Colon Cancer via STAT3 Signaling 
Abstract 
Myc-associated zinc finger (MAZ) is a transcription factor highly upregulated in chronic 
inflammatory disease and several human cancers. In the current study, we found that MAZ 
protein is highly expressed in human ulcerative colitis and colon cancer. However, the precise 
role for MAZ in the progression of colitis and colon cancer is not well defined. To determine the 
function of MAZ, a novel mouse model of intestine epithelial specific MAZ overexpression was 
generated. Expression of MAZ in intestinal epithelial cells was sufficient to enhance 
inflammatory injury in two complementary models of colitis. Moreover, MAZ expression 
increased tumorigenesis in an in vivo model of inflammation-induced colon cancer and was 
important for growth of human colon cancer cell lines in vitro and in vivo. Mechanistically, 
MAZ is critical in the regulation of oncogenic STAT3 signaling. MAZ expressing mice have 
enhanced STAT3 activation in the acute response to colitis, Moreover, MAZ was essential for 
cytokine and bacteria-induced STAT3 signaling in colon cancer cells. These data indicate an 
important functional role for MAZ in the inflammatory progression of colon cancer through 
regulation of STAT3 signaling and suggest MAZ is a potential therapeutic target to dampen 




 Colon cancer remains a significant public health concern and is the third-leading cause of 
cancer-related deaths in the United States (1). The tumor-associated inflammatory response is 
well-characterized as a key contributor to neoplastic progression, in part through activation of 
oncogenic signaling pathways in tumor cells, such as STAT3 and NF-"B (2). Myc-associated 
zinc finger (MAZ) is an inflammation-induced cys2his2-type zinc finger transcription factor that 
is highly active in inflammatory foci and previously has been suggested to be a critical driver of 
inflammation in animal models (3). Moreover, MAZ is highly expressed in cancer of the 
pancreas, liver, breast, and prostate (4-7). MAZ has three splice-variants (MAZ1, MAZ2, and 
MAZ3). MAZ splice-variants 1 and 3 are activated by inflammation, whereas MAZ2 is anti-
inflammatory (8, 9). Our previous work has identified an essential role for MAZ in hypoxia-
driven inflammatory responses in both colitis and colon cancer (10). MAZ is a direct protein 
interactor of the hypoxia-inducible transcription factor (HIF-2a) and is important for HIF-2a 
transactivation of inflammatory target genes, such as tumor necrosis factor a (Tnfa) (11, 12). 
However, HIF-2a-independent functions for MAZ in the progression of colitis and colon cancer 
are relatively unknown.  
Signal transducer and activator of transcription 3 (STAT3) is an inflammation responsive 
transcription factor with an important role in the progression of several cancers (13). STAT3 
signaling is activated by inflammatory cytokines such as IL-6, IL-10, and IL-22 and plays a key 
role in the development of Th17 cells (14). In intestinal epithelial cells, STAT3 signaling is an 
essential mediator of epithelial repair processes in the resolution of colitis downstream of IL-22 
(15). Polymorphisms associated with STAT3 and STAT3 signaling pathway have been identified 
in both ulcerative colitis and Crohn’s disease, suggesting an important role in the progression of 
	 110 
human inflammatory bowel disease (IBD) (16). In addition to the prominent role for STAT3 in 
colitis, STAT3 is an essential transcription factor for the progression of colitis associated colon 
cancer (CAC). Genetic disruption of STAT3 in intestinal epithelial cells decreases susceptibility 
to inflammation-induced colon cancer and chronically active STAT3 increases susceptibility to 
colon tumorigenesis (17). Deletion of the STAT3 activating cytokine IL-6 also reduced CAC 
(18). STAT3 activation downstream of microbial sensing pathways is also an important 
mechanism linking inflammation and colon cancer (19). Under normal circumstances, 
mechanisms exist to rapidly dampen STAT3 activation (20). In tumors STAT3 is chronically 
activated, suggesting tumor-specific factors maintain high STAT3 and drive neoplastic 
progression. Discovering factors essential in sustaining high STAT3 activation may provide 
novel druggable targets for the treatment of colon cancer.  
In the current study, it was demonstrated that MAZ was restricted to epithelial cells and 
was highly expressed in both inflammatory disease as well as neoplastic disease of the colon. To 
dissect the role of MAZ in colitis and colon cancer, a novel model of transgenic epithelial-
specific MAZ overexpressing mice was generated. RNA-sequence analysis from the transgenic 
mice found that MAZ regulates a novel repertoire of HIF-2a-independent genes. MAZ was an 
important driver of the inflammatory response in complementary models of chemically-induced 
and infectious colitis models. Moreover, MAZ expression significantly increased tumorigenesis 
in an inflammation-induced colon tumor model, suggesting MAZ was a novel link between 
inflammation and cancer of the colon. Mechanistically, a novel function for MAZ in the 
maintenance of STAT3 signaling both in vivo and in vitro was observed. This work delineates 
and important role for MAZ in the inflammatory response in colitis and colon cancer and 
suggests MAZ as a novel therapeutic target to dampen STAT3.  
	 111 
Methods 
Animals and treatments 
Mice expressing MAZ under control of the 12.4kb villin-promoter were generated (21). 
The mouse MAZ cDNA was subcloned from pET-16B plasmid into the Mlu1 and Kpn1 sites of 
the pUC12.4kb-villin promoter construct. The plasmid was then digested with Pme1 and used to 
generate vilMAZ mice in collaboration with the University of Michigan Transgenic Animal Core. 
vilMAZ mice were backcrossed to C57BL/6 mice for 5 generations. For all experiments, male 
and female mice aged 6 to 8-weeks were used. For dextran sulfate sodium (DSS)-colitis, vilMAZ 
and WT littermate controls were treated with 2.5% wt/vol DSS in drinking water for 7-days. For 
Salmonella enterica serovar Typhimurium (S. Typhi) colitis, mice were pretreated by oral 
gavage with streptomycin (7.5mg/mouse) and 24-hours later were orally gavaged with 1x107 
colony-forming units of S. Typhi. Citrobacter rodentium-colitis was induced with oral gavage of 
1x107 colony-forming units of C. rod in 6- to 8-week old mice WT mice. Azoxymethane 
(AOM)/DSS-induced tumorigenesis was induced in 6- to 8-week old vilMAZ and WT littermate 
controls. Mice were I.P. injected with AOM at (10mg/kg) then cycled on and off 2% DSS in 
their drinking water beginning 5-days following intial injection of AOM for 7-days with 14-days 
of regular drinking water interspersed between. Mice were sacrificed 100-days after AOM 
injection. For subcutaneous tumor growth, 1x106 HCT116 cells were prepped in 37oC 1x PBS 
and injected subcutaneously into the flanks of Nude mice. Nude mice were housed in autoclaved 
cages in facility specifically designed for housing immunodeficient mice and fed irradiated food 
and autoclaved water. Germ free mice were housed in the University of Michigan Germ Free 
core and treated with AOM/DSS as described above. Germ free mice were conventionalized with 
a single gavage of feces from WT mice. TLR2/4 double knockout mice were previously 
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described (22). All experiments were carried out using guidelines and approved by the 
University Committee on the Use and Care of Animals at the University of Michigan.  
 
Human tissue 
Human IBD and colon cancer tissue was procured at the University of Michigan per 
Institutional Review Board approval and guidelines. 
 
Cell culture and cell treatments 
HCT116, MCA38, and human embryonic kidney (HEK) cells were cultured in 
Dulbecco’s Modified Eagle Media (DMEM) supplemented with 10% FBS and 1% anti-
biotic/anti-mycotic. Cells were cultured at 370C and 5% CO2 and 21% O2. STAT3 response 
luciferase assay (SIE) was conducted by co-transfection of SIE luciferase plasmid with pCDNA 
MAZ1 or MAZ3 into cells using polyethylinimine (PEI) reagent. 24-hours after transfection, 
cells were treated with IL-6 (10ng/ml) for 12-hours. Standard luciferase assay was performed as 
previously described and normalized to ß-galactosidase activity (12). MAZ knockdown HCT116 
cells were generated as previously described (11). For IL-6 treatments, cells were seeded in 6-
well plates at a density of 3x10^5/well. 24 hours later, cells were treated with IL-6 (10ng/ml) for 
30, 60, and 120 minutes. For JAK1/2 inhibition studies, HEK293T or HCT116 cells were 
transfected 500ng of pCDNA MAZ1 and MAZ3 for 24-hours then treated with 3!M Ruxolitinib 
or DMSO for 12-hours. For co-immunoprecipitation experiments, MAZ was co-transfected with 
human myc-JAK1 or myc-JAK2 expression construct for 48-hours. Cells were lysed and myc-
immunoprecipitation was performed using Myc-TRAP beads as described in manufacturers 
protocol (Chromotek). For S. Typhi treatment, HCT116 and HT29 cells were seeded at a density 
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of 3x10^5 cells/well in a 6-well plate. 24-hours later cells were washed 3x with PBS then treated 
with 1x10^6 CFUs of S. Typhi for 4- and 8-hours. siRNA transfection was performed using 
Lipofectamine 2000 reagent (Thermo Fisher Scientific) and 5µM MAZ or Ctrl siRNAs (Santa 
Cruz Biotechnology). Cell growth was monitored using 3-(4,5-dimethyl-2-thiazoly)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) reagent.  
 
Histology and immunofluorescence 
Colon tissue was excised, washed with cold PBS, and cut longitudinally. Tumors were 
sized and counted and then colon tissue was rolled and fixed in 10% formalin for 12-hours. 
Tissues were then embedded in paraffin. 5µm tissue sections were stained with hematoxylin and 
eosin and all histological analysis was done in a blinded manner as previously described (11). 
Inflammation scoring was based on crypt damage, inflammation, depth of injury, and percentage 
of tissue affected. Immunofluorescence of human ulcerative colitis was performed with frozen 
sections which were fixed with 10% formalin for 10-minutes, permeabilized with 0.5% Triton X-
100 for 10-minutes, then blocked with 5% goat serum for 1-hour. Slides were then incubated 
with primary antibody for MAZ overnight (1:100, Abcam). Proliferation analysis was performed 
on paraffin embedded tissue slides following citrate buffer antigen retrieval using Ki67 antibody 
(Vector Laboratories). 
 
Protein isolation and western blotting 
Western blots were performed as previously described (11). Antibodies against MAZ 
(1:1000, Active Motif), GAPDH (1:1000, Santa Cruz Biotechnology), phospho-STAT3 (1:1000, 
Cell Signaling Technologies), total-STAT3 (1:1000, Cell Signaling Technologies), phosho-P38 
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(1:1000, Cell Signaling Technologies), total-P38 (1:1000, Cell Signaling Technologies), 
phospho-AKT (1:1000, Cell Signaling Technologies), total-AKT (1:1000, Cell Signaling 
Technologies), pJNK (1:1000, Cell Signaling Technologies), total-JNK (1:1000, Cell Signaling 
Technologies), phospho-JAK (1:1000, Cell Signaling Technologies), and total-JAK (1:1000, 
Cell Signaling Technologies) were used for blotting. Secondary horseradish peroxidase-
conjugated antibodies (Cell Signaling Technologies) were used for protein detection.  
 
Colon tumor enteroids 
Patient-derived colon tumor and normal tissue enteroids were generated as previously 
described (23). 
 
RNA isolation and qPCR analysis 
RNA was isolated using isol-RNA lysis reagent and qPCR analysis was performed as 
previously described (24). Primers are listed in Supplemental Table 3.1. Expression analysis was 
normalized to $-Actin expression.  
 
RNA-seq and RNA-seq data analysis 
RNA sequencing was performed as previously described (10). Briefly, the TruSeq RNA 
library prep kit v2 (Illumina) was used to prepare RNA sequencing libraries The libraries were 
sequenced using single-end 50-cycle reads on a HiSeq 2500 sequencer (Illumina).  The Flux 
high-performance computer cluster at the University of Michigan was used for computational 
analysis. RNA-seq read quality was assessed utilizing FastQC. Reads were aligned to a splice 
junction aware build of the mouse genome (mm10) using STAR(25) with the options 
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“outFilterMultimapNmax 10” and “sjdbScore 2”. Differential expression testing between WT 
and vilMAZ colon samples was conducted with CuffDiff v 2.1.1 with the parameter settings “-
compatible-hits-norm,” and “–frag-bias-correct”. We used UCSC mm10.fa and the GENCODE 
mouse M12 primary assembly annotation GTF as the reference genome and reference 
transcriptome, respectively. Genes were considered differentially expressed at a false-discovery 
rate-adjusted (FDR) P value of <0.05. 
 
Statistical analysis 
P-values were calculated by students t-test, paried t-test, or one-way ANOVA. 
Differential expression of mRNA expression with qPCR was calculated using deltadeltaCT 




Intestine epithelial MAZ regulates a novel repertoire of genes 
 MAZ is an important transcriptional cofactor in the hypoxic inflammatory response 
through direct interaction with HIF-2a and directing the pro-inflammatory HIF-2a 
transcriptional response (11). However, the precise functional role for MAZ in the progression of 
inflammation in colitis has not been assessed. To delineate the function of MAZ in the 
inflammatory progression of colitis a mouse model of intestinal epithelial-specific MAZ 
overexpressing transgenic mice was generated. cDNA for MAZ expressing a N-terminal FLAG-
tag was cloned into the previously described 12.4kb Villin-promoter construct to drive MAZ 
expression to the intestine epithelium; hereby referred to as vilMAZ mice (21). MAZ and FLAG 
protein expression were verified from colon and small intestine lysates from WT and vilMAZ 
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mice (Fig. 4.1A). Maz transcript expression was 3-fold higher in colonic tissue and 12-fold 
higher in small intestine tissue from vilMAZ mice (Fig. 4.1B). Histologic analysis shows no 
observable differences in colonic architecture in untreated mice (Fig. 4.1C). Subcellular 
fractionation of colon tissue from WT and vilMAZ mice showed the vast majority of MAZ 
protein in vilMAZ mice was localized to the nucleus (Fig. 4.1D). No changes in expression of 
inflammatory cytokines Tnfa and Il1$, or colon lineage markers Muc2, Tff3, Chga, or Cdh1 were 
observed (Fig. 4.1E). RNA-sequencing analysis was performed on colon tissue to determine 
genes differentially expressed in intestinal tissue of vilMAZ mice. Several novel genes including 
a number of inflammation-associated genes regulated by epithelial MAZ expression were 
identified (Fig. 4.1F). Interestingly, only 24% of significantly changed genes identified in 
vilMAZ RNA-seq corresponded with identified genes in RNA-seq from colon tissue of HIF-2a 
expressing animals (10) suggesting a repertoire of HIF-2a-independent target genes (Fig. 4.1G). 
qPCR validation of several targets confirmed MAZ expression significantly increases expression 
of Gatsl3, which encodes an arginine sensing protein, as well as the lncRNA Fer1l4. Moreover, 
MAZ expression decreased expression of the antimicrobial peptide Ang4 and the zinc transporter 
Slc30a10 (Fig. 4.1H). These results identify a novel repertoire of MAZ-regulated genes in colon 
epithelial cells, most of which do not overlap with genes directly regulated with HIF-2a.  
 
MAZ potentiates the acute inflammatory response in colitis 
 MAZ protein is highly expressed in several inflammatory models including inflammatory 
arthritis (9). However, MAZ protein expression has never been analyzed in inflammatory disease 
of the colon. MAZ protein was significantly upregulated in mucosal biopsy specimens from 
patients with ulcerative colitis (UC) compared to normal patient controls (Fig. 4.2A). The vast 
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majority of MAZ protein in UC was localized to inflamed colon epithelial cells (Fig. 4.2B). 
Interestingly, increased MAZ protein expression was not observed in ileal biopsy specimens 
from Crohn’s Disease (CD) (Fig. 4.2C). This suggests a potential role for colon epithelial MAZ 
in the inflammatory progression of colitis. The RNA-seq data demonstrates that MAZ regulates 
several genes known to be important inflammatory targets. An acute model of colitis was 
initiated by treatment of WT and vilMAZ mice with 2.5% dextran sulfate sodium (DSS) in the 
drinking water for seven days then changed back to regular drinking water for three days. 
Compared to WT animals, vilMAZ animals lost significantly more weight and failed to recover 
body weight (Fig. 4.2D). MAZ-expressing mice had moderately shorter colon lengths after DSS-
colitis suggesting heightened inflammation (Fig. 4.2E). Histologic analysis shows a robust 
inflammatory cell infiltrate and disruption of colonic architecture and histological scoring 
confirmed that MAZ-expressing transgenic animals had robustly higher inflammation in DSS-
induced colitis compared to WT mice (Fig. 4.2F & G). These data suggest that epithelial MAZ 
expression is sufficient to increase inflammation in acute DSS-colitis and that MAZ upregulation 
in human ulcerative colitis may potentiate disease progression. 
 
MAZ is regulated by colon microbiota and sensitizes mice to bacteria-induced colitis 
Microbial dysbiosis is now well appreciated as a critical driver of inflammation and 
disease progression in IBD (26). MAZ expression has previously been shown to be regulated by 
microbial products (27). To assess the role for pathogenic microbes in the regulation of MAZ 
protein in colitis, a Salmonella enterica serovar Typhimurium (S. Typhi) murine model of colitis 
was assessed. The S. Typhi model of murine colitis can recapitulate many of the aspects 
observed in human colitis (28). WT mice were pretreated with streptomycin and then inoculated 
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with S. Typhi. Robust MAZ protein expression is observed in a time-dependent manner at 5 and 
10-days following inoculation (Fig. 4.3A).  
To further delineate the role for pathogenic microbes in MAZ induction, we used the 
Citrobacter rodentium (C. Rod) model of colitis (29). In mice treated with C. Rod for 10-days, 
MAZ protein was also robustly induced (Fig. 4.3B). Both S. Typhi and C. rod induce robust 
colonic inflammation, therefore, it is possible the activation of MAZ in these tissues may be 
indirect through inflammatory mediators.  
To determine if bacteria directly activated MAZ, colon cancer-derived cell lines HCT116 
and HT29 were infected with S. Typhi in vitro. MAZ protein was increased as early as 4-hours 
and was sustained through 8-hours after infection (Fig. 4.3C). To address if basal maintenance of 
MAZ protein is microbiota-dependent, germ free (GF) and conventionalized (Conv) mice were 
assessed. Compared to GF colon tissue, microbiota conventionalization upregulated MAZ 
protein in colon tissue suggesting that microbiota are critical for basal expression of MAZ (Fig. 
4.3D). Futhermore S. Typhi was sufficient to promote robust MAZ expression in WT mice but 
not toll-like receptor (TLR)2/4 double KO mice (Fig. 4.3E) suggesting that LPS-dependent TLR 
signaling is a key-mediator of MAZ upregulation in colitis. To assess the role for MAZ in 
bacterial-derived colitis, WT and vilMAZ mice were treated with S. Typhi for 10-days. vilMAZ 
mice had significantly enhanced inflammation in bacterial colitis compared to WT mice, 
suggesting activation of MAZ in bacterial-colitis is a critical step in the inflammatory response 
(Fig. 4.3F & G). 
 
MAZ expression increases colitis-associated colon tumorigenesis 
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Inflammation and cancer of the colon are linked (30). Our data show that MAZ 
expression is sufficient to increase inflammation in models of acute colitis. To model 
inflammation-dependent colon tumorigenesis, an AOM/DSS colon tumor model was assessed 
(Fig. 4.4A) (31). Compared to WT mice, vilMAZ mice develop significantly more colon tumors 
and had higher tumor burden in the inflammation-induced AOM/DSS model (Fig. 4.4B-D). 
Moreover, tumors from vilMAZ mice had a higher proportion of actively proliferating cells (Fig. 
4.4E). This observation suggests an important role for activation of epithelial MAZ in the 
transition from chronic inflammation to colon cancer.   
We next assessed the requirement for microbiota in MAZ protein induction in 
inflammation induced colon tumors. GF and SPF mice were subjected to AOM/DSS-induced 
tumorigenesis. SPF mice demonstrated a robust MAZ expression in colon tumors compared to 
adjacent normal colon tissue, MAZ expression in GF mice was dramatically reduced in the 
adjacent normal colon tissue, compared to SPF mice, and the increased tumor-associated MAZ 
expression was ablated (Fig. 4.4F). Collectively, these data suggest microbial-mechanisms are 
essential for MAZ activation in inflammation-induced colon tumors and that this axis increases 
disease severity.  
 
MAZ protein is highly expressed in human colon cancer and has cell autonomous roles in 
colon cancer growth. 
MAZ has an important role in the induction of inflammation-driven colon cancer in vivo. 
Moreover, increased MAZ protein expression is observed in tumor tissue compared to adjacent 
normal colon tissue in ten colorectal cancer (CRC) patients (Fig. 4.5A). MAZ protein expression 
was assessed in human normal tissue or colon tumor enteroids. Colon tumor enteroids are 
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derived from primary patient colon tumor epithelial cells and maintain three-dimensional 
structure and cell polarity (23). Interestingly, MAZ protein was highly induced in patient-derived 
colon tumor enteroids compared to normal colon enteroids suggesting MAZ is upregulated in 
epithelial cells of colon cancer patients (Fig. 4.5B). Oncomine data analysis suggests MAZ 
mRNA is decreased in human colon tumors compared to normal colon (Fig. 4.5C). The Cancer 
Genome Atlas (TCGA) analysis shows significant decrease of MAZ mRNA in human colon 
cancer relative to normal colon tissue (Fig. 4.5D). qPCR analysis of matched patient normal and 
colon tumor tissue shows that 7/10 patients have a relative decrease in the tumor MAZ mRNA 
(Fig. 4.5E). Collectively, these data suggest that in human colon cancer, novel mechanisms 
promoting the activation of MAZ protein are established independent of MAZ transcripts to 
promote tumorigenesis and tumor growth. 
MAZ protein was expressed in varying degrees across a panel of several different human 
colon cancer cell lines (Fig. 4.5F). To determine if MAZ is important for colon cancer growth, 
siRNAs that robustly reduced expression of MAZ in cell lines were tested (Fig. 5G). In HCT116, 
SW480, and HT29 cells, siRNA-mediated MAZ knockdown significantly reduced colon cancer 
cell growth in vitro (Fig. 4.5H). Furthermore, HCT116 cells with shRNA-mediated MAZ 
knockdown grow significantly slower than control shRNA (shCtrl) expressing HCT116 cells in 
subcutaneous tumor model in Nude mice (Fig. 4.5I). These data suggest MAZ has important 
functions for regulating colon cancer growth independent of the enhanced inflammatory 
response in the AOM/DSS model.   
 
MAZ expression induces STAT3 activation in acute colitis 
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No direct regulator of MAZ-mediated cell growth was identified in the RNA-sequence 
analysis. To address mechanisms by which MAZ expression enhances colon cancer growth 
colon tissue from WT and vilMAZ mice were screened to analyze pathways that are important in 
driving colon tumorigenesis in both sporadic and CAC models (Fig. 4.6A). Epithelial MAZ 
expression correlated with heightened STAT3 phosphorylation (Fig. 4.6A). STAT3 is an 
inflammation-induced transcription factor that is an essential driver of tumorigenesis in CAC and 
sporadic colon cancer (17, 32). To determine if MAZ-induced STAT3 activation was cell 
autonomous, MAZ transcript variants 1 and 3 (MAZ1 & MAZ3) were expressed in HEK cells. 
Western blot analysis shows both MAZ1 and MAZ3 expression robustly induced STAT3 
phosphorylation (Fig. 4.6B). To delineate if this led to heightened STAT3 transcriptional 
activity, STAT3-responses element luciferase reporter (SIE) was assessed. In colon-cancer 
HCT116 cells, expression of MAZ1 and MAZ3 dramatically potentiated IL-6-induced STAT3 
transcriptional activity (Fig. 4.6C). These data suggested that MAZ-induced STAT3 activation 
was independent of enhanced inflammation in colitis. Interestingly, no difference in STAT3 
activation was observed in tumor tissue from WT or vilMAZ mice. However, colon tumor 
induced MAZ expression in WT mice was relatively equivalent to the observed MAZ protein 
expression in tumors of vilMAZ mice (Fig. 4.6D). Furthermore, knockdown of MAZ in HCT116 
cells dramatically reduced STAT3 phosphorylation in response to IL-6 at all time points assessed 
(Fig. 4.6E). This also led to decreased STAT3 transcriptional response as MAZ knockdown 
significantly blunted SIE luciferase activity in response to IL-6 (Fig. 6F). In colon cancer, IL-6 
and IL-11 are key cytokines in STAT3 activation and tumor progression (33). However, bacterial 
products also regulate STAT3 signaling, specifically products derived from Salmonella (34). 
Treatment with S. Typhi in MAZ knockdown cells led to significantly reduced STAT3 activation 
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compared to control cells (Fig. 4.6G). Additionally, siRNA knockdown of MAZ in mouse colon 
cancer cell line MCA38 and HEK cells also show reduced STAT3 responsiveness to IL-6 (Fig. 
4.6H & I). These results delineate an essential role for MAZ in regulation of STAT3 activation in 
colon cancer cells in response to both cytokine and bacterial stimuli. Moreover, the data suggests 
MAZ serves as a link between inflammation-induced STAT3 signaling and colon cancer.  
 
MAZ regulates STAT3 signaling in a JAK-dependent manner 
 STAT3 is activated in response to extracellular cytokines whose receptors promote the 
activation of Janus Kinases (JAKs) through the adaptor protein GP130 (35). Under normal 
circumstances, JAK-mediated STAT3 activation was rapidly inhibited by various negative 
feedback mechanisms. To assess the requirement for JAK in MAZ-dependent STAT3 activation, 
the JAK1/2 inhibitor Ruxolitinib was assessed. In HCT116 and HEK cells, expression of both 
MAZ1 and MAZ3 were sufficient to induce STAT3 phosphorylation. However, in cells treated 
with Ruxolitinib, the increased STAT3 phosphorylation was completely ablated (Fig. 4.7A & B). 
MAZ knockdown decreased phosphorylated JAK in colon cancer cells suggesting MAZ is a 
novel regulator of JAK activation (Fig. 4.7C). Interestingly, MAZ knockdown did not decrease 
mRNA expression of any of the major components of the STAT3 signaling cascade (Fig. 4.7D). 
Furthermore, no direct interaction of MAZ with either JAK1 or JAK2 could be detected by co-









MAZ was discovered more than two decades ago, however, relatively little is known 
about the function of MAZ in normal physiology or the disease state. MAZ was first described as 
a factor binding to the cMYC promoter (36). Since then several MAZ direct target genes have 
been described. Our previous work has shown an essential role for MAZ in the hypoxic 
progression of colitis and MAZ is a direct protein interactor of HIF-2a (12). HIF-2a 
transcription of the pro-inflammatory cytokine Tnfa was MAZ-dependent (11). Moreover, HIF-
2a dependent expression of Caveolin-1, which increased acute inflammation in colitis through 
decreased epithelial barrier integrity, was MAZ-dependent (12). Our previous data suggested that 
MAZ was an important HIF-2a cofactor and directed HIF-2a to promoters of inflammatory 
target genes. Using a novel mouse model of intestine epithelial specific MAZ expression, our 
current data suggest HIF-2a-independent functions of MAZ in the inflammatory progression of 
colitis and colon cancer. A novel repertoire of MAZ regulated genes and pathways have been 
identified.  
 MAZ was highly active in inflammatory foci and was highly expressed in inflamed 
tissues of rheumatoid arthritis patients. Transgenic MAZ expressing mice have previously been 
shown to potentiate the inflammatory response in an infectious model of arthritis (3). 
Mechanistically, MAZ regulates transcription of mmp1 and mmp9 in inflamed joint tissue (37, 
38). MAZ expressing animals have heightened susceptibility to develop serum amyloidosis, a 
condition associated with chronic inflammation due to rheumatoid arthritis and Crohn’s disease 
(39). Consistent with the previous data, we have shown that intestine epithelial MAZ expression 
is sufficient to enhance the acute inflammatory response in complementary models of infectious 
and chemically induced colitis. Previous work has identified MAZ regulation through 
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inflammatory stimuli including IL-6, IL-1B, and LPS (40, 41). In monocytic cells, direct LPS 
treatment is sufficient to drive MAZ expression (27). Moreover, these studies have identified 
inflammation-dependent phosphorylation events which regulate MAZ transcriptional potential 
(42). In the current study, we propose that pathogenic microbes are key regulators of MAZ 
protein expression. We find that MAZ is robustly induced in two separate bacterial models of 
colitis. MAZ protein was also induced in GF mice when colonized with microbiota from SPF 
mice. Pathogenic bacteria can directly induce MAZ protein in colon cancer cells independent of 
an underlying inflammatory response. Furthermore, microbiota are essential for MAZ protein 
expression in colon tumors. Microbial dysbiosis is critical in activating inflammation in human 
colitis and human colon cancer (43). Thus, it is perhaps possible that the increased MAZ protein 
we observed in human ulcerative colitis patients is in part due to microbial dysbiosis and direct 
activation by colon microbiota. Increased MAZ expression observed in colitis may serve to 
enhance the inflammatory response through HIF-2a-dependent as well as independent 
mechanisms and provide a critical link between chronic inflammation and colon cancer.  
Several mechanisms for MAZ-dependent regulation of tumor growth and progression 
have been proposed. In hepatocellular carcinoma, MAZ was shown to regulate EMT signature 
genes to promote tumor invasion (4). In breast cancer, MAZ was shown to transcriptionally 
regulate expression of both HRAS and KRAS to direct tumor angiogenesis (44). Additionally, 
MAZ can directly drive angiogenesis in triple negative breast cancer cells through direct 
transcriptional regulation of VEGF (7). In prostate cancer, MAZ can regulate tumor cell growth 
through activation of androgen receptor expression (5). Furthermore, in pancreatic cancer MAZ 
is a regulator of KRAS transcription and therapeutic targeting of MAZ interaction with KRAS 
promoter using decoy oligonucleotides shows efficacy in decreasing tumor growth (45). This 
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method also showed efficacy in preclinical bladder cancer models (46). In the current study, 
using novel epithelial specific transgenic MAZ overexpressing mice, MAZ expression is 
sufficient to enhance tumorigenesis in an inflammation-induced model. Furthermore, MAZ was 
shown to have cell autonomous regulation of cell growth in colon cancer cell both in vitro and in 
vivo. Recently, our work suggested an important role for MAZ in the inflammatory progression 
of colon cancer by regulating HIF-2a-mediated expression of the potent neutrophil chemokine 
Cxcl1 (10). In the current study, we have discovered a novel HIF-2a-independent function for 
MAZ in the regulation of STAT3 signaling.  
Persistent STAT3 activation is observed in human colon cancer and epithelial expression 
of STAT3 is a crucial link between inflammation and cancer of the colon. Intestine epithelial 
specific STAT3 knockout mice develop very few tumors in CAC (17). Conversely, transgenic 
mice with a constitutive activation of intestinal epithelial STAT3 develop significantly more 
tumors in the same model (17). STAT3 activation is transient and negatively regulated by 
various intracellular proteins including SOCS3. In tumors STAT3 is persistently elevated 
through unknown mechanisms. Previous studies have suggested intra-tumoral iron as an 
important mediator of STAT3 maintenance in colon tumors (47). Furthermore, the negative TLR 
signaling regulator IRAK-M has been shown to maintain STAT3 signaling through increased 
STAT3 protein stability, linking microbial sensing to STAT3 maintenance (19). MAZ was found 
to be sufficient to increase STAT3 phosphorylation in acute colitis in vivo as well as in cell lines. 
Moreover, MAZ was essential for the activation of STAT3 in response to both cytokine and 
bacterial stimuli. MAZ protein was highly upregulated in human colon cancer, suggesting that 
MAZ upregulation in colon cancer is a necessary event to maintain STAT3 activation at high 
levels. Recent evidence suggests MAZ is a key regulator of both AKT signaling pathways in 
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pancreatic cancer cells (48). However, no changes to AKT activation were detected in the 
vilMAZ mice (Fig. 6A). Our combination of in vivo and in vitro data suggest MAZ may provide a 
novel therapeutic target to dampen colon cancer associated inflammatory responses through 
reduction of STAT3 signaling and may have efficacy for treatment of patients. Interestingly, 
MAZ did not transcriptionally alter any key components of the JAK/STAT3 signaling pathway 
and no known direct regulators of this pathway were discovered in RNA-sequence data. 
Moreover, MAZ did not directly interact with JAK1 or JAK2, suggesting novel mechanisms 
integrating MAZ and JAK/STAT3 signaling. Interestingly, JAKs have several post-translational 
modifications including phosphorylation, acetylation, and ubiquitylation, most of which are not 
well understood or characterized in their functional regulation of JAK activity (49). Further 
investigation aimed at understanding how MAZ may regulate JAK activity and protein 
modifications will be important to address how MAZ modulates the activation of STAT3.  
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Figure 4.1. Generation of intestine-epithelial specific MAZ transgenic mice. (A) Western 
blot analysis of MAZ and FLAG expression in colon and small intestine (S.I.) extracts from WT 
and vilMAZ mice. (B) qPCR analysis of MAZ transcript and (C) representative images of 
hematoxylin and eosin (H&E) staining from colon tissue of WT and vilMAZ mice. (D) Western 
analysis of MAZ protein expression in cytosolic (C) and nuclear (N) extracts from colon tissue 
of WT and vilMAZ mice. Lamin A/C and GAPDH are nuclear and cytosolic markers 
respectively. (E) qPCR analysis of indicated genes from colon tissue of WT and vilMAZ mice. 
(F) Heat map of RNA-seq data WT and vilMAZ. (G) Venn diagram of genes identified as 
overlapping with HIF-2a RNA-seq and vilMAZ-independent genes. (H) qPCR confirmation of 
several MAZ target genes identified in (F) from WT and vilMAZ colon tissue. Statistical analysis 
was performed with Student’s t test. The error bars represent standard error. *** p=0.001; ** 





Figure 4.2. MAZ expression enhances the acute inflammatory response in colitis. (A) 
Western blot analysis of MAZ expression in human ulcerative colitis (UC) and normal tissue 
biopsy samples. Each lane represents a different patient. (B) Immunofluorescence of MAZ in 
human UC frozen tissue section. (C) Western blot analysis of MAZ expression in human 
Normal, UC, and Crohn’s Disease (CD) biopsy specimens. (D) Body weight (E) colon length (F) 
histologic inflammation score and (G) H&E analysis from WT and vilMAZ mice treated with 
2.5% DSS. Statistical analysis was performed with Student’s t test. The error bars represent 





Figure 4.3. MAZ is regulated by microbiota and increases inflammation in bacterial-driven 
colitis. (A) Western blot analysis of MAZ expression in mice treated with S. Typhi colitis for 5-
days and 10-days. (B) Western analysis of MAZ expression in mice treated with C. rod colitis 
for 10-days. (C) Western blot analysis of MAZ expression in HT29 and HCT116 cells treated 
with S. Typhi for 4-hours and 8-hours. (D) Western blot analysis of MAZ expression in colon 
tissue from germ free mice and germ free (GF) mice reconstituted with microbiota (Conv). (E) 
Western blot analysis of MAZ expression in colon tissue from WT and TLR2/4DKO mice 
treated with and without S. Typhi colitis for 10-days. (F) H&E and (G) total inflammation score 
of WT and vilMAZ mice treated with S. Typhi colitis for 10-days. Statistical analysis was 












Figure 4.4. MAZ expression increases colitis-associated colon tumorigenesis. (A) Schematic 
of AOM/DSS model. (B) Tumor number (C) tumor burden (D) and H&E analysis of WT and 
vilMAZ animals treated with AOM/DSS colon tumorigenesis. (E) Representative 
immunofluorescence staining of Ki67 in indicated tumor tissue. (F) Western blot analysis of 
MAZ expression in tumor and adjacent normal tissue from specific pathogen free (SPF) and 
germ free (GF) mice with AOM/DSS-induced colon tumorigenesis. Statistical analysis was 
performed with Student’s t test. The error bars represent standard error. **p<0.01; *p<0.05 
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Figure 4.5. MAZ is important for human colon cancer growth. (A) Western blot analysis of 
MAZ expression in human colon tumor (T) biopsies compared to adjacent normal tissue (N). (B) 
Western blot analysis of MAZ expression normal colon tissue (NT) (n=2) and colon tumor 
enteroids (n=2). (C) Oncomine database analysis of MAZ expression in human colon cancer 
relative to normal colon controls in independent microarrays. (D) MAZ gene expression from 
The Cancer Genome Atlas. (E) MAZ expression in a matched set of 10 colon tumors and 
adjacent normal. (F) Western blot analysis of MAZ expression in indicated human colon cancer 
cell lines assessed in duplicate. (G) Western blot analysis of MAZ expression in HEK cells 
treated with Ctrl or MAZ-targeting siRNAs. (H) MTT assay of cell growth in HCT116, HT29, & 
SW480 cells treated with Ctrl or MAZ targeting siRNAs. (% of Day 0). (I) Tumor weight of 28-
days after subcutaneous injection of HCT116 cells stably transfected with control shRNA 
(shCtrl) or two different MAZ shRNAs (shMAZa or shMAZb) into nude mice. Statistical 
analysis was performed with Student’s t test. The error bars represent standard error. 




Figure 4.6. MAZ is a novel regulator of STAT3 signaling. (A) Western blot analysis of 
phosphorylated AKT, STAT3, JNK, and P38 in WT and vilMAZ mice treated with 2.5% DSS for 
7-days. (B) Western blot analysis of pSTAT3 in HEK cells expressing MAZ transcript variants 1 
& 3. (C) STAT3 luciferase activity analysis of HCT116 cells expressing MAZ transcript variants 
1 & 3 treated with PBS or IL-6 (10ng/ml) for 12-hours. Data shown as fold change over control 
****p<0.0001. (D) Western blot analysis of pSTAT3 expression in tumor and adjacent normal 
tissue from WT and vilMAZ mice. (E) pSTAT3 analysis in HCT116 cells expressing MAZ 
shRNAs treated with IL-6 (10ng/ml) for 30, 60, and 120 minutes. (F) STAT3 luciferase activity 
analysis of HCT116 cells expressing MAZ shRNAs treated with IL-6 (10ng/ml) for twelve 
hours. Data shown as fold change over control. ****p<0.0001. (G) pSTAT3 western blot 
analysis in HCT116 cells expressing MAZ shRNAs treated with S. Typhi for 4-hours. 
Phosphorylated STAT3 western blot analysis in (H) MCA38 cells or (I) HEK cells transfected 
	 137 
with MAZ siRNAs for 24-hours then treated with IL-6 (10ng/ml) for 60-minutes. Statistical 











Figure 4.7. MAZ regulates JAK-mediated STAT3 activation. Western blot analysis of (A) 
HCT116 and (B) HEK cells expressing MAZ transcript variants 1 & 3 pretreated with Ctrl or the 
JAK inhibitor for 12-hours. (C). pJAK and pSTAT3 western blot analysis in HCT116 cells 
expressing MAZ shRNAs treated IL-6 (10ng/ml) for 30, 60, and 120 minutes. (D) qPCR analysis 
of STAT3 signaling component genes in MAZ knockdown HCT116 cells. (E) Western blot 
analysis of myc-immunoprecipitation from HEK cells expressing myc-JAK1 and MAZ or (F) 
myc-JAK2 and MAZ. 
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Table S1: qPCR Primers 
Mouse 
Primers Forward (5'-3') Reverse (5'-3') 
!-Actin TGAAGCAGGCATCTGAGGG CGAAGGTGGAAGAGTGGGAG 
Maz ACCACCTGAACCGACATAAGCT GGCACACAGGGCACTGGTA 
Fer1l4 CCGTGTTGAGGTGCTGTTC GGCAAGTCCACTGTCAGATG 
Slc30a10 TGTGGTCATCACGGCTATCAT ATGTAGCACTGCCAGTTACAC 
Ang4 ACAACAAAGGACATGGGCTC TCTCCAGGAGCACACAGCTA 
Gatsl3 CACGGAGCCACTGTGAGATA ACACTCTCATGGTGGATGAGG 
Tnf! AGGGTCTGGGCCATAGAACT CCACCACGCTCTTCTGTCTAC 
Il1! AAGAGCTTCAGGCAGGCAGTATCA TGCAGCTGTCTAGGAACGTCA 
Tff3 GCACCATACATTGGCTTGG AGAGCCCTCTGGCTAATGCT 
Muc2 CCTGAAGACTGTCGTGCTGT GGGTAGGGTCACCTCCATCT 
Chga GTCTCCAGACACTCAGGGCT ATGACAAAAGGGGACACCAA 
Cdh1 AAAAGAAGGCTGTCCTTGGCC GAGGTCTACACCTTCCCGGT 
   Human Primers Forward (5'-3') Reverse (5'-3') 
!-Actin TATTGGCAACGAGCGGTTCC GGCATAGAGGTCTTTACGGATGT 
hMAZ TCGGCTTATATTTCGGACCA CATTGGACAAACCTCACCAGT 
hJAK1 GAATGACGCCACACTGACTG GATGACAAGATGTCCCTCCG 
hJAK2 CCATTCCCATGCAGAGTCTT CAGGCAACAGGAACAAGATG 
hJAK3 GGACAAGAGGCTGCATGAAC CTTCGAAAGTCCAGGGTCC 
hGP130 CGGACAGCTTGAACAGAATGT ACCATCCCACTCACACCTCA 
hSTAT3 CTGCTCCAGGTACCGTGTGT CCTCTGCCGGAGAAACAG 
hIL6R ACTGGTCAGCACGCCTCT GGGACCATGGAGTGGTAGC 









Conclusions and Future Directions 
Epithelial HIF-2a is a well characterized activator of the intestinal inflammatory 
response in the setting of colitis. HIF-2a directly targets expression of a battery of cytokines and 
chemokines to promote mucosal inflammatory responses. In addition to its role in colitis, the 
work in this thesis provides convincing evidence of the role of the colon epithelial hypoxic 
response and HIF-2a activation as critical regulators of inflammation-induced colon 
tumorigenesis. Disruption of intestinal epithelial HIF-2a significantly reduces colon 
tumorigenesis in complementary inflammation-induced tumor models. Moreover, constitutive 
activation of HIF-2a in mice with epithelial deletion of Vhl enhanced colon tumorigenesis, 
suggesting HIF-2a is both an essential and sufficient regulator of colitis-associated colon 
tumorigenesis in mice.  
Our previous work has shown that HIF-2a can modulate the colon tumor inflammatory 
response via distinct pathways. HIF-2a is a direct transcriptional regulator of cyclooxygenase-2 
(COX-2) and microsomal prostaglandin e synthase (mPGES) to increase tumor-associated 
inflammation and inflammatory prostaglandin production (1). Moreover, HIF-2a is essential for 
colon tumor uptake of iron and intra-tumoral iron increases tumor associated inflammation and 
oncogenic cytokine production (2). The work in this thesis extends this data to show that HIF-2a 
can directly modulate the tumor immune microenvironment through recruitment of PMNs. 
Deletion of intestinal epithelial HIF-2a led to significant reduction of colon tumor-associated 
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PMNs in complementary models of colitis-associated colon cancer. Furthermore, expression of 
epithelial HIF-2a is sufficient to increase PMN recruitment into colon tissue and colon tumors. 
Mechanistically, this was downstream of HIF-2a transcription of the potent PMN chemokine 
Cxcl1.  
CXCL1 is highly expressed in sites of inflammation and several solid tumor through 
unknown mechanisms. This thesis shows that the colon tumor epithelium is an important and 
major source of CXCL1 in a HIF-2a-dependent manner. Deletion of epithelial HIF-2a 
significantly reduced colon tumor CXCL1 mRNA and protein abundance. The Cxcl1 proximal 
promoter contains several hypoxia response elements (HREs) and HIF-2a activation of the 
Cxcl1 promoter is HRE-dependent. Inhibition of the CXCL1 receptor, CXCR2, using inhibited 
tumorigenesis in a HIF-2a-driven tumor model. These data demonstrate an essential role for 
epithelial HIF-2a in modulating the tumor microenvironment and suggest targeting HIF-2a 
therapeutically may show benefit in colon cancer patients. Our work also extends previous data 
showing that epithelial HIF-1a does not play a significant role in inflammation-induced colon 
cancer. This is consistent with our prior work which showed hyper-activation of HIF-1a did not 
promote colon tumorigenesis (3). Taken together, the work in this thesis to extend upon the 
function of HIF-2a in colitis-associated colon cancer and identifies HIF-2a as an important link 
between inflammation and cancer. Furthermore, this work defines HIF-2a as a master regulator 
of Cxcl1 expression and PMN recruitment into colon tumors. With the development of novel 
HIF-2a-specific inhibitors, future studies in our lab will be aimed at modulating HIF-2a activity 
in preclinical murine colitis and colon cancer models with an impetus toward clinical 
development of these drugs.  
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HIF-based therapeutics in cancer 
Due to the highly complex role of HIF in tumorigenesis, HIF-based therapies need to be 
assessed on an individual tumor basis. The best-characterized approach to alter HIF signaling is 
through inhibiting PHDs, which leads to activation of HIF signaling (4). PHD inhibitors have 
been assessed in models of inflammation-induced tissue injury and were shown to be effective 
and safe (5-7). Through a decrease in inflammation-induced tissue injury, PHD inhibitors may 
have a beneficial role in several cancers. Recent work has clearly demonstrated that PHD 
inhibitors can selectively activate HIF-1a (8). This suggests the possibility of finding novel 
agents that may target each isoform. However, there are concerns about therapeutic activation of 
HIF signaling, as most data suggest that HIF pathways lead to enhanced tumor progression. 
Currently, there are several drugs that inhibit HIF-1a and many of them are in clinical trials (9). 
Most of the compounds that are in clinical trials were originally discovered as targeting other 
pathways. 2-methoxyestradiol, a metabolite of estradiol, can decrease tumor growth through 
inhibition of HIF-1a but simultaneously can decrease angiogenesis and disrupt microtubules 
(10). Cardiac glycosides, including Digoxin, can robustly reduce tumor growth through 
inhibition of HIF-1a (11). Furthermore, several topoisomerase inhibitors have been shown to 
decrease tumor growth through HIF-1a inhibition (12, 13). However, no HIF-1a specific 
inhibitors have been discovered.  
Selective inhibition of HIF-2a can be achieved through targeting the iron response 
element in the 5’-UTR of HIF-2a (14). Additionally, through structural analysis of HIF-2a, a 
ligand-binding cavity located within its PAS-B domain, which contains a b-sheet that mediates 
interaction with ARNT. This cavity is not present on HIF-1a. (15). No endogenous ligands are 
known for HIF-2a, but this cavity has been targeted for drug development and several promising 
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highly specific small molecule inhibitors have been identified as efficaciously disrupting HIF-2a 
heterodimerization with ARNT and blocking DNA binding and transcription of target genes in 
cultured cells (16). These inhibitors have shown efficacy in preclinical models of renal cell 
carcinoma, which is driven by HIF-2a (17, 18). Our data in colon cancer suggest inhibition of 
HIF-2a may dampen tumor growth and progression through several mechanisms. HIF-2a has 
cell-autonomous effects in colon cancer cells through hyper-activation of iron uptake via divalent 
metal transporter 1 (Dmt1) (2). Interestingly, our lab has recently discovered a unique HIF-2a-
dependent mechanism of colon tumor iron trapping through a local hepcidin axis (Andrew 
Schwartz, unpublished data). These data in addition to the data in this thesis show HIF-2a can 
inhibit cell-autonomous growth and decrease tumor-associated inflammation. The current 
available reagents coupled with recent HIF structural analysis provide a framework to 
specifically regulate HIF-1a and HIF-2a and provide clinical tools to alter tumor pro-tumor 
inflammatory response or anti-tumor-immune response in both colitis and colon cancer (19). 
 
Neutrophils and colon cancer 
The data in this thesis extends previous work suggesting that PMNs are critical drivers of 
tumor growth and progression. However, most studies rely upon PMN trafficking receptor 
inhibitors or antibody-mediated PMN depletion in established tumors. Inhibition of PMNs using 
CXCR2 blocking peptide suggested that PMNs play an important role in tumorigenesis in 
hypoxic-driven and established tumors (20). The primary contribution of PMNs to the induction 
of colon tumors is less clear. Our studies suggest that complete PMN ablation prior to the 
induction of colon tumorigenesis using LysM-Cre-driven Mcl1 deletion dramatically enhances 
colon tumor growth and progression. In the AOM/DSS colitis-associated colon cancer model, 
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greater than 60% of PMN-deficient animals developed highly invasive adenocarcinoma. This 
was able to be recapitulated in sporadic colon tumor models by generating PMN-deficient 
chimeric Cdx2-CreERT2; Apcfl/fl mice. Strikingly, we observed invasive adenocarcinoma in this 
model at 14-days after colon tumor induction. Mechanistically, PMN-deficiency increased colon 
tumor-associated bacteria, genetic instability, and heightened inflammatory response through IL-
17 expression and NF-"B signaling. Furthermore, antibiotics treatment was able to reverse the 
increased tumor growth and progression in PMN-deficient mice in the AOM/DSS model of 
colitis-associated colon cancer. These studies suggest an important role for PMNs in the 
restriction of tumor-associated microbes to decrease colon tumor progression. This thesis 
suggests divergent and even opposing functions of PMNs in colon cancer and suggest more 
study into PMN heterogeneity and kinetics of PMN are warranted.  
Limitations to our studies include the LysM-Cre used for Mcl1 deletion. Cre expression 
downstream of the LysM promoter is activated in all myeloid cells, therefore although only 
PMNs are depleted in this model, off target effects cannot be completely excluded. However, the 
PMN-specific Mrp8-Cre and the myeloid LysM-Cre phenocopied each other in a sporadic colon 
tumor model suggesting this effect was due specifically to PMN depletion and not off target 
effects in other myeloid cells. Other genetic models of PMN depletion have been generated, 
including the Csf3r knockout mouse which fails to develop PMNs (21).  
Our data suggest that temporal regulation of PMNs may be critical to exert either pro- or 
anti-tumor effects. Interestingly, human studies of early stage lung cancer have suggested that 
PMNs from early stage tumors are T-cell stimulatory and as lung cancers progress PMNs 
become less T-cell stimulatory (22). In mouse-models of colon cancer, inhibition of PMNs after 
the initiation of colon tumorigenesis suggests PMNs promote tumor growth and progression. 
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However, in human colon cancer, it has been proposed that early PMN infiltration into colon 
tumors is associated with positive prognosis (23). Future studies should be aimed at identifying 
temporal evolution of intra-tumoral PMNs in colon cancer. This could be done using Cre-
dependent Diphtheria Toxin Receptor (DTR) expressing mice for PMN depletion (24). Mrp8-Cre 
expressing mice can be crossed to mice expressing DTR down-stream of a loxp-STOP-loxp 
cassette that has been previously described. For these experiments three groups in which PMNs 
are depleted with Diphtheria Toxin prior to AOM/DSS-induced tumorigenesis, PMN depletion 
after the third cycle of DSS, and a group in which PMNs are depleted after induction of colon 
tumorigenesis. Moreover, temporal control of PMN depletion could be achieved by generation of 
a tamoxifen-inducible LysM-Cre or Mrp8-Cre mouse. These studies and mouse models will more 
precisely define the dependence of PMNs during different stages of colon tumorigenesis.  
 Depletion of PMNs prior to the initiation of colon tumorigenesis increases colon tumor 
progression through limiting microbiota-dependent responses. However, other anti-tumor 
mechanisms of PMNs in early stage colon cancer are largely undefined. Previous studies have 
suggested that PMNs in early stage lung cancers acquire antigen presenting cell (APC) functions 
and can activate anti-tumor T-cell responses (25). It has also been reported that PMNs in acute 
colitis acquire APC functions suggesting PMNs may inhibit initiation of colon tumorigenesis 
through activation of T-cell responses (26). It would be interesting to examine the contribution of 
PMN-APCs in the initiation of colitis-associated colon tumorigenesis. For these studies, 
previously described mice with floxed major histocompatibility complex II (MhcII) alleles are 
being crossed to Mrp8-Cre mice (27). Coupling AOM/DSS as well as sporadic colon cancer 
models may provide clues into the role of PMN-dependent antigen presentation in the initiation 
of colon tumorigenesis.  
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MAZ and regulation of STAT3 signaling 
Our lab has suggested that the cellular microenvironment can modulate the hypoxic 
response and HIF-2a target gene specificity. For example, low iron status activates intestinal 
epithelial HIF-2a. In this setting, HIF-2a activates transcription of numerous genes related to 
iron absorption but not inflammatory target genes. Current work in our lab suggest this effect is 
in part mediated by SMAD3/4 signaling (Nupur Das, unpublished data). Interestingly, in the 
inflamed state epithelial HIF-2a activates transcription of inflammatory target genes but not iron 
absorption. We have previously identified Myc-associated zinc finger (MAZ) as a direct HIF-2a 
interacting protein (28). MAZ is a cys2-his2 type zinc finger transcription factor that is highly 
upregulated in chronic inflammatory diseases and several human cancers. Although its 
expression is induced in several models, very little is known of its function in inflammation and 
cancer. We have shown that MAZ is crucial for HIF-2a-dependent inflammatory target gene 
specificity in colitis and colon cancer. We first identified MAZ as an essential factor for HIF-2a-
dependent transcription of Tnfa (29). Interestingly, although HIF-2a directly binds to and 
regulates activation of the Tnfa promoter, no HIF-2a binding site is present in the Tnfa proximal 
promoter. Deletion of a MAZ binding site in the Tnfa proximal promoter completely ablated 
HIF-2a-dependent Tnfa induction (29). This thesis extends on our previous data to show that 
MAZ is also important for HIF-2a-dependent Cxcl1 activation. However, the precise functional 
role and HIF-2a-independent functions of MAZ are not known.  
The work in this thesis demonstrates that MAZ is highly induced in human ulcerative 
colitis and colon cancer. To delineate the function of MAZ, we generated a novel mouse model 
of intestine epithelial-specific MAZ expression. MAZ expression dramatically enhanced 
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susceptibility to colitis and complementary models of chemically-induced and bacterial colitis 
(DSS & S. Typhi). Moreover, MAZ expression enhanced the susceptibility to colitis-associated 
colon tumorigenesis in the AOM/DSS model and was important for the growth of human colon 
cancer cells both in vitro and in vivo. Mechanistically, we have identified an important role for 
MAZ in the regulation of oncogenic STAT3 signaling. STAT3 is an inflammation-induced 
transcription factor that is absolutely essential for the initiation and maintenance of colon 
tumorigenesis (30). STAT3 is highly activated and maintained in human colon cancer through 
unknown mechanisms. We show that both in vivo and in vitro MAZ promotes increased 
activation of STAT3. Moreover, knockdown of MAZ in colon cancer cells reduces 
responsiveness of STAT3 to inflammatory stimuli. These data suggest targeting MAZ may 
provide a novel therapeutic avenue to dampening STAT3 activation in colon cancer.  
To address more mechanistically the role of MAZ in inflammation and cancer we have 
used CRISPR/CAS9 to generate full body knockout mice. Guide RNAs targeting the first exon 
of MAZ and founders were identified that were heterozygous for an 11-base pair deletion of 
exon 1 (Fig. 5.1A). Interestingly, MAZ protein expression downregulated but is not completely 
lost in these mice, suggesting hypomorphic expression (Fig. 5.1B). This is perhaps the result of 
alternative splicing. MAZ has an upstream exon used in alternative splicing, which bypasses 
MAZ exon 1, may bypass the deletion of MAZ in our knockout mice. Interestingly, basal STAT3 
phosphorylation in the small intestine and colon of these mice is reduced relative to WT 
littermate controls suggesting that these mice still may provide an effective model for the study 
of MAZ in colitis and colon cancer (Fig. 5.1C). Additionally, the lab is generating mice with 
floxed Maz alleles. These mice will be crossed to intestine epithelial Villin-Cre expressing mice 
to be used for further analysis of MAZ in colitis and colitis-associated colon tumor models.  
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The exact mechanism of MAZ-dependent STAT3 activation is unknown. The work in 
this thesis suggests MAZ activates STAT3 in a JAK-dependent mechanism. However, MAZ 
does not transcriptionally regulate expression of JAK1, JAK2, or JAK3 or have direct interaction 
with JAK1 or JAK2 suggesting a novel mechanism of JAK regulation. Future experiments in the 
lab including screening for novel MAZ protein interactors using BioID, a method which allows 
identification of protein interactors by conjugating a protein of interest to a biotin ligase which 
biotynylates interacting proteins (31). Furthermore, the lab is investigating genome wide MAZ 
binding sites using MAZ chromatin immunoprecripitation (ChIP). Further delineation of the 
mechanism by which MAZ regulates the STAT3 signaling cascade may provide insight into 
mechanisms maintaining high STAT3 phosphorylation in colon cancer.  
 
Final thoughts 
 The data in this thesis clearly shows that epithelial HIF-2a is essential in inflammation-
induced colon tumorigenesis. The present work demonstrates that PMN inhibition in established 
tumors can therapeutically decrease tumor growth. Interestingly, evidence suggest that HIF-2a 
expression in immune cells is also important in colon tumorigenesis (32). Therefore, this work 
combined with previous work provides rationale for the continued development of HIF-2a-
specific inhibitors in the treatment of colon cancer. The data in this thesis also challenges the role 
of intra-tumoral PMNs in colon cancer. We show that inhibition of PMNs in established tumors 
reduces tumor progression. However, we also show that depletion of all PMNs prior to initiation 
of tumorigenesis increases colon tumor growth and progression in complementary inflammation-
induced and sporadic colon tumor models. Our data suggest an important role for intra-tumoral 
PMNs in restricting microbe-dependent tumor responses. Therefore, more evaluation of PMN 
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evolution and heterogeneity in colon cancer must be considered before initiating clinical trials in 
human colon cancer patients. This thesis also delineates a novel function for the HIF-2a 
interacting protein MAZ in the regulation of oncogenic STAT3 signaling. Therefore, targeting 
MAZ may be effective in dampening the pro-inflammatory HIF-2a response as well as reduce 
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Figure 5.1 Generation of full-body MAZ knockout mice. (A) Sanger sequencing analysis of 
11-bp deletion in Exon 1 of MAZ. + = MAZ positive control. (B) Western blot analysis of MAZ 
expression in duodenum, ileum, and colon tissue of one WT mouse and two separate 11-bp MAZ 
knockout mice. (C) pSTAT3 western blot analysis in small intestine (S.I.) and colon tissue from 
indicated mice.  
 
 
